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Abstract 
Background: Treatment effects differ across patients. To guide selection of 
treatments for patients, it is essential to acknowledge these differences and identify 
moderators or predictors. Our aim was to generate optimal search strategies 
(commonly known as filters) for PubMed to retrieve papers identifying moderators 
and predictors of treatment effects. 
Methods: Six journals were hand-searched for articles on moderators or predictors. 
Selected articles were randomly allocated to a development and validation set. Search 
terms were extracted from the development set and tested for their performance. 
Search filters were created from combinations of these terms and tested in the 
validation set. 
Results: Of 4407 articles, 198 were considered to be relevant. The most sensitive 
filter in the development set ‘(“Epidemiologic Methods” [MeSH] OR assign* OR 
control*[tiab] OR trial*[tiab]) AND therapy*[sh]’ yielded in the validation set a 
sensitivity of 89% [88%–90%] and a specificity of 80% [79%–82%]. 
 
 
Conclusions: The search filters created in this study can help to efficiently retrieve 
evidence on moderators and predictors of treatment effect. Testing of the filters in 
multiple domains should reveal robustness across disciplines. These filters can 
facilitate the retrieval of evidence on moderators and predictors of treatment effects, 
helping the implementation of stratified or personalised health care. 
Keywords: evidence-based medicine (EBM); information retrieval; PubMed; search 
strategies 
Key messages 
 The potential of a treatment to be clinically effective can be improved if factors that 
predict whether or how well a treatment works, predictors and moderators, are 
included in clinical decision making.  
 Optimal search strategies (commonly known as filters) are developed and tested 
that can retrieve up to 90% of the articles describing predictors and moderators 
of treatment effects.  
 Information on predictors and moderators is necessary to facilitate research on 
stratified or personalised health care.
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Background 
It is increasingly recognised that patients respond to treatments in different ways 
(Kravitz, Duan & Braslow, 2004) and that treatments that have been demonstrated to 
be sufficiently safe on average may still produce serious side-effects in some patients 
(Bast & Hortobagyi, 2004; Evans & Relling, 2004).  
The full potential of a treatment is more likely to be realised if it is targeted according 
to the biological or risk characteristics shared by subgroups of patients. Therefore, 
those developing clinical guidelines or making individual patient treatment decisions 
need to search the medical literature for studies providing information on the effect 
of patient characteristics on treatment effects. Factors that predict whether a 
treatment works or not are known as ‘predictors’; factors that influence how well a 
treatment works compared to other options (usually measured by an interaction 
term) are labelled ‘moderators’ (Baron & Kenny, 1986; Kraemer, Wilson, Fairburn & 
Agras, 2002).  
Search strategies (commonly known as filters) can facilitate searches for moderators 
and predictors. They can help researchers to find relevant literature more quickly and 
easily by reducing the number of articles that a researcher needs to review or allowing 
a busy clinician to identify a more relevant set of articles within a fixed amount of time 
(Shariff et al., 2012). Existing search filters have been mainly developed to efficiently 
retrieve high quality literature on aetiology, diagnosis, prognosis and therapy 
(Chatterley & Dennett, 2012; Hoogendam, de Vries Robbe, Stalenhoef & Overbeke, 
2009; Huang et al., 2016; McKibbon, Wilczynski, Haynes & Team, 2009). One set of 
filters, the PubMed Clinical Query filters, has been developed to find literature on 
prognosis, treatment or clinical prediction. This original set of filters can be used to 
retrieve articles concerning diagnosis or disease staging, study design/methodology, 
clinical prediction (i.e. prognosis, independent of treatment), outcome measures 
(including patient reported outcomes and quality of life) or treatment effects in 
general. However, these pre-existing filters focus on studies investigating a 
 
 
homogeneous population, or an ‘average’ patient, and not specifically on moderators 
and predictors. 
Objectives 
The aim of this study was to create search filters to aid in the retrieval of literature on 
moderators or predictors of treatment effect. 
Methods 
For the development and validation of the search filters for PubMed, two steps were 
taken: (1) a comprehensive set of search terms and combinations of terms were 
extracted from a set of manually selected relevant papers; and (2) the retrieval 
performance of these combinations of terms was tested. The methods used followed 
accepted good practice in search filter creation (Jenkins, 2004; White, Glanville, 
Lefebvre & Sheldon, 2001). 
Creation of a set of relevant papers (reference set) 
First, we constructed a set of relevant papers by hand searching journals for papers 
concerning moderators or predictors of treatment effects (containing predictor or 
moderator analysis as primary or secondary outcome). As an exemplar domain, we 
selected the field of rheumatology, where personalised health care is becoming 
increasingly important (Burgos, Danila, Kelley, Hughes & Bridges, 2009; Gibson et al., 
2012). Four journals (Annals of the rheumatic diseases, Arthritis care & research, 
Arthritis research & therapy, and Arthritis and rheumatism) were selected according 
to their ranking, based on the 5-year Impact Factor in the rheumatology category 
(Institute of Scientific Information Journal Citation Reports), and supplemented with 
two high impact general clinical journals (the Lancet and the New England Journal of 
Medicine). 
 
As a first round of screening, all articles published in these journals in the year 2011 
were manually screened in PubMed by title and abstract and classified as possibly 
 
 
concerning research on moderators or predictors of treatment effects. Any article 
describing an intervention which either describes in the abstract that moderator, 
predictor or subgroup analyses were performed, or that gives a strong indication that 
such factors are investigated, was selected for review. This could include not only RCTs 
but also any intervention study mentioning regression or subgroup analysis. The year 
2011 was selected to allow proper MeSH-term linkage. The following inclusion criteria 
were used: clinical trials phase III, randomised controlled trials, systematic reviews, 
meta-analyses, guidelines and/or studies reporting on moderators, predictors, 
biomarkers or genetic factors related to treatment outcomes. Studies performing 
safety analysis were also included. 
 
Case reports, comments, editorials, clinical trials phase I and II news and in vitro or 
animal studies were excluded, as well as studies reporting on predictors of prognosis 
or diagnosis. Although we used rheumatology as an exemplar domain, we included 
non-rheumatology related papers as well to increase generalisability of findings 
outside the field of rheumatology. Articles were restricted to the English language. The 
first screening was performed by two authors independently (WK and CL or MT and 
CL); if at least one reviewer considered the article to be potentially relevant, it was 
included for subsequent full-text examination.  
 
Full texts of the articles selected during the first round of screening were retrieved 
and subjected to a second round of screening. For inclusion, articles had to mention 
at least one variable that influenced a treatment outcome, for example as interaction 
term in a model or stratification variable. Articles were included regardless of study 
quality, evidence level or direction or size of effect. Each full-text article was 
independently screened by two authors (WK and CL or MT and CL). A third author 
(WK, MT, RvH or GJvdW) was consulted if the authors were unsure or no agreement 
was achieved. The final set of articles was designated as a ‘reference set’ and used to 
generate search terms and determine retrieval performance. 
 
 
Search terms 
The entire set of articles (both relevant and irrelevant) was randomly divided into a 
development set and a validation set. The development set was used to create the 
search filters, and the validation set was used to test the search filters. The reference 
papers in the development set were submitted to PubReMiner to generate a list of all 
keywords (including truncated keywords to accommodate variations in grammatical 
form) and MeSH terms related to these articles. PubReMiner is an online tool that 
creates frequency tables of various properties of submitted queries (Cunningham et 
al., 1998). Three authors (WK, MT and RvH) filtered out common general terms (e.g. 
‘method’, ‘conclusion’ and ‘objective’), which lack discriminatory power, as well as 
disease-specific terms related to diagnoses, treatment procedures or outcomes 
(excluding only if there was a unanimous decision). This evaluation was performed on 
the meaning of the terms, not the amount of studies they did or did not cover. The 
remaining keywords and MeSH terms were selected for testing. Each keyword was 
included with and without specified search fields (text word [tw], title or abstract 
[tiab], title [ti], MeSH Major Topic [majr], MeSH Subheadings [sh] or MeSH Terms 
[mh]). 
Testing search filters 
The retrieval performance of each search filter (consisting of a single term or 
combination of search terms) was determined using four accepted measures. 
The sensitivity (Se), specificity (Sp), accuracy (Ac) and number needed to 
read (NNR) were calculated according to the formulas listed in Table 1.
 
 
 
Table 1 - Formulas for calculating the sensitivity, specificity and number needed to read 
Sensitivity: A/(A + C); specificity: D/(B + D); accuracy: (A + D)/(A + B + C + D); number 
needed to read: 1/[A/(A + B)].
 
 Relevant Not relevant Total 
Identified 
A (true positives, correct 
inclusion) 
B (false positives, incorrect 
inclusion) Total identified 
Not 
identified 
C (false negatives, incorrect 
exclusion) 
D (true negatives, correct 
exclusion) 
Total not 
identified 
Total A + C (total relevant hits) B + D (total not relevant 
hits) 
A + B + C + D 
(total database) 
 
 
 
Sensitivity, in this context, is a measure of the proportion of relevant articles 
retrieved from the reference set. Specificity is a measure for the nonretrieval 
of non-relevant citations (McKibbon et al., 2009). Accuracy is defined as the 
proportion of articles correctly retrieved by the search filter (Haynes, 
McKibbon, Wilczynski, Walter & Werre, 2005). The number needed to read is 
defined as the total number of articles to be screened to retrieve one relevant 
article (Bachmann, Coray, Estermann & Ter Riet, 2002). It is the inverse of 
‘precision’, but easier to interpret for those less familiar with the term.  
 
All terms were tested individually, and those with a Se <25% and Sp <75% 
were excluded from further analysis. Our methods resembled those used by 
Haynes, Wilczynski, McKibbon, Walker and Sinclair (1994) and sought to 
exclude keywords with high Se but unusably low Sp or vice versa. Where 
similar keywords with different search fields had the same Se and Sp, we 
excluded the most restrictive term (e.g. from treat* [tiab] and treat* [tw], the 
first was excluded in case of equal Sp and Se). To improve face validity, some 
specific terms (linked with moderators, predictors or their analysis) were 
included in the subsequent step irrespective of their performance as a single 
term. This is not expected to do any harm, as the creation process would filter 
out these terms if they were not performing well.  
  
In a second step, multi-term search filters were tested. To improve face 
validity of the search filters, the search terms were divided into terms related 
to treatment outcome (T-term) (e.g. ‘outcome’, ‘treatment’) and terms 
related to moderators/predictors or methodology (M-term) in the broader 
sense (e.g. ‘randomised’, ‘trial’). Classification was performed by three authors 
 
 
(MT, WK and RvH) using majority rule. Some terms were classified as neutral 
(M- and T-term) because they could not be classified as either of these two. 
An initial set of multi-term search filters was created by combining one T-term 
and one M-term using a Boolean ‘AND’ operator. Combinations with a Se <75%, 
a Sp <50% or an Ac <75% were removed. The remaining combinations were 
combined one by one with the other M-terms and T-terms using an ‘OR’ 
operator with the existing M-terms or T-terms in the filter (i.e. ‘(T-term1 OR 
T-term2) AND (M-term1 OR M-term2)’). If the performance measures of this 
combination improved (with Se, Sp and Ac remaining at S75%, S50% and S75%, 
respectively), the extra term was considered to offer additional value. In a 
computational algorithm, written in C++, additional search terms were tested 
until no further improvement could be made. Optimal combinations of search 
terms per filter were generated for each performance measure separately. 
 
The performance of the search filters was determined by applying the search filters 
to the validation set to obtain the required measures. 
Sensitivity analysis 
To check for generalisability across journals from a specific domain (rheumatology) 
and general clinical journals, we compared the performance of the search filters within 
the rheumatology journals and the general clinical journals separately. 
Results 
Creation of a set of relevant papers (reference set) 
A total of 4407 articles were selected for hand searching; the search string is presented 
in Appendix A. In total, 198 papers were classified as papers providing information on 
moderators of predictors of treatment effect (see Appendix B). An overview of the 
screening process is presented in Figure 1. Table 2 shows the number of papers in the 
development and validation set per journal. 
 
 
Search terms 
Submitting the 97 papers that were considered relevant to PubReMiner yielded 1253 
MeSH terms and 1231 keywords. Each keyword was combined with six different search 
fields ([tw], [tiab], [ti], [majr], [sh] and [mh]) or used without any field delimiters 
resulting in a total of 9870 single-term (7 9 1231 + 1253) searches to be performed in 
PubMed. Among these, 314 terms resulted in a Se S25% and a Sp S75%. Of these 314 
terms, 121 terms were removed as they were too disease-specific or too general 
(Appendix C). A list of items (fixed terms) which were forced into the algorithm to 
improve face validity is also displayed in Appendix C. The distribution of the remaining 
193 terms into M-terms, T-terms or neutral terms is shown in Appendix D. 
 
 
 
 
Figure 1 Manual search for relevant papers. *One paper reporting on a case series 
and cohort study was not excluded, because none of the index patients were part 
of the cohort (Korswagen et al.). **One paper was marked in PubMed as a clinical 
trial, Phase II. However, this paper reported a randomised controlled phase III 
study and was therefore not excluded based on publication type (Tak et al.) 
 
 
 
Testing search filters 
Table 3 shows the best single-term filters, and Table 4 shows the best multi-term filters 
optimised for Se, Sp, Ac and NNR separately. 
 
When search terms from the development set were applied to the validation set, a 
decrease in sensitivity (ca. 10%) was observed, but not in specificity. Accuracy 
decreased by ca. 1%, and NNR increased by ca. 0.5. (Table 4, rightmost columns). The 
most sensitive filter with the highest Sp (‘Epidemiologic Methods’ [mesh] OR assign* 
OR control*[tiab] OR trial*[tiab]) AND therapy*[sh]) had a Se of 89% and Sp of 80%, 
and on average, 5.6 papers need to be screened in order to retrieve one relevant paper. 
The combination (group*[tw] AND therapy*) reduces the NNR to 2.8 and increases Sp 
by about 15%, at the cost of 30% loss in Se. 
 
 
Table 2 Number of papers in the development set, the validation set and total 
number of papers considered relevant in the hand search per journal and in total 
 
Development set 
(relevant papers) 
Validation set 
(relevant papers) 
Total 
(relevant 
papers) 
Annals of the rheumatic diseases 235 (16) 205 (14) 440 
(30) 
Arthritis care and research 133 (4) 145 (8) 278 (12) 
Arthritis research and therapy 158 (4) 156 (4) 314 (8) 
Arthritis and rheumatism 255 (10) 271 (12) 526 (22) 
Lancet 714 (28) 738 (27) 1452 (55) 
The New England Journal of 
Medicine 
723 (35) 674 (36) 1397 (71) 
Total 2218 (97) 2189 (101) 4407 
(198) 
Table 3 Single-term filters with the best sensitivity, best specificity, best accuracy 
and the lowest number needed to read for detecting papers reporting on 
moderators or predictors of treatment effects 
Search term Se (%) [95% CI] Sp (%) [95% CI] Ac (%) NNR 
Best 
sensitivity† 
treat* 95.9 [95.0–96.7] 79.5 [77.9–81.2] 80.3 5.67 
trial* 86.6 [85.2–88.0] 88.3 [87.0–89.6] 88.2 3.95 
controll* 80.4 [78.8–82.1] 91.5 [90.4–92.7] 91.0 3.31 
Best specificity† 
intent*[tiab] 29.9 [28–31.8] 98.9 [98.4–99.3] 95.9 1.83 
registered 29.9 [28–31.8] 98.8 [98.4–99.3] 95.8 1.86 
randomise*[ti] 28.9 [27–30.8] 98.8 [98.4–99.3] 95.8 1.89 
Best accuracy† 
intent*[tiab] 29.9 [28–31.8] 98.9 [98.4–99.3] 95.9 1.83 
registered 29.9 [28–31.8] 98.8 [98.4–99.3] 95.8 1.86 
randomise*[ti] 28.9 [27–30.8] 98.8 [98.4–99.3] 95.8 1.89 
Lowest NNR† 
intent*[tiab] 29.9 [28–31.8] 98.9 [98.4–99.3] 95.9 1.83 
registered 29.9 [28–31.8] 98.8 [98.4–99.3] 95.8 1.86 
 
 
Sensitivity analysis 
When the validation set was restricted to the four rheumatology journals, 
performance measures degraded slightly. In the filters optimised for Se, the average 
Se dropped from 91% to 78%. In the filters optimised for Sp, the average Sp dropped 
from 95% to 92%. Ac dropped from 93% to 90% in the Ac-optimised filters, and NNR 
rose from 2.9 to 5.1 in the NNR-optimised filters. When the validation set was restricted 
to the two core clinical journals, the performance measures increased; average Se 
rose to 98%, Sp rose to 96%, Ac rose to 95% and NNR dropped to 2.2. 
Discussion 
To our knowledge, this study is the first to report search filters for the retrieval of 
articles specifically on moderators or predictors of treatment effects. The most 
sensitive filter is appropriate if comprehensiveness is sought, at the expense of 
efficiency. If efficiency is more important, a more specific but less sensitive filter is 
appropriate, in particular the combination (group*[tw] AND therapy*). For retrieval of 
more recent articles which are not yet indexed, we suggest using a filter without either 
MeSH headings or subheadings. 
 
 
 
 
 
 
In the absence of other search filters for finding literature on moderators or 
predictors of treatment effects, we can compare the efficiency of the resulting filters 
with those of established search filters (e.g. Haynes et al., 1994; Wilczynski, Walker, 
McKibbon & Haynes, 1993). These search filters are used to retrieve aetiology, 
prognosis, diagnosis or treatment related studies, and target a variety of study types 
with no specific subject, similar to our filters. The methods of development and 
validation used by these authors are comparable to our own. As in these studies, our 
study revealed many combinations of keywords reaching >95% Se or Sp. The results 
from our study showed an optimal NNR for multiterm filters between 2.5 and 5.7, 
comparable to those reached by Haynes et al. (reaching an NNR of 1.7–4.8, calculated 
from table 7 in Ref. (Haynes et al., 1994). Because our filters will also retrieve relevant 
information from non-RCTs, they appear to have added value to the PubMed Clinical 
Queries (PCQ) filter for therapy. If these PCQ filters (broad filters) are applied to our 
validation set, they yield a slightly higher Se (94%) at the cost of a lower Sp (64%) and 
higher NNR (9.0), where our filters reached 89% Se, 80% Sp and NNR of 5.6. The 
differences between this filter and our filters can be explained by the fact that the PCQ 
filters are more generally focussed on treatment effects, which results in a broader 
set of articles returned often excluding moderators or predictors, hence the higher Se 
and lower Sp. The Sp optimised PCQ filters (narrow filters) perform similar to our 
filters at a Sp of 95% with a Se of 64% and only slightly higher NNRs (3.0 versus our 
2.8). The fact that our filters and the PCQ filters optimised for Sp perform similarly can 
be explained by the fact that both aim to select articles on treatment effectiveness. 
Although in the validation set the differences may be small, our filters do provide added 
benefit over the PCQ filters if one is specifically interested in moderators or predictors 
of treatment effects due to their higher specificity, as is evident from the lower NNRs. 
 
The strength of this study is that we tested the retrieval performance of a wide range 
of candidate search terms (keywords and MeSH terms). Furthermore, combining 
these terms using an algorithm allowed us to test well over a million different 
 
 
combinations. The distinction in keyword types (M- and T-terms, respectively) allowed 
a predefined place for an AND operator within the search filters, a satisfactory 
alternative to testing search filters with all possible combinations of OR and AND 
operators next to the number of keywords. Furthermore, this prevented us from 
generating search filters that only contained terms relating to a limited number of 
methods used to determine moderators or predictors. In short, we were directed to 
include both methodology and treatment related terms in the filters (improving 
generalisability and face validity). 
 
Our selection of reference articles contained a large number of general medicine 
articles (126 of 198; 64%), most of which were RCTs. A total of 138 RCTs were in the set 
(42% of all RCTs in the six journals), while only seven papers described systematic 
reviews. This may explain the fact that terms related to trials yielded individually the 
highest Se and Sp. The results from the sensitivity analysis support this assumption, as 
the final set of best search filters performed much better on the core clinical journals 
(with a higher density of RCTs) compared to the rheumatology journals. This may imply 
that the search filters are more sensitive to RCTs than other types of studies. However, 
non-RCTs will still be picked up by our filters. 
 
Our study has several limitations. The first relates to the selection methods we used, 
that is expanding only search terms and combinations, which yielded adequate Se and 
Sp. This selection method was used to prevent drops in performance measures while 
optimising other performance measures (e.g. dropping Sp while optimising Se and vice 
versa), while also bringing down the number of combinations to a more manageable 
size by only expanding search term combinations that reached performance 
thresholds. Although this approach is very similar to other work considered as best 
practice (Haynes et al., 1994), the selection method may become too strict in cases 
where search terms have a synergistic effect. In our view, the methods used make a 
 
 
good compromise between restricting the amount of combinations and allowing good 
combinations to improve. 
 
Second, we made no distinction between predictors and moderators when selecting 
articles while recognising a conceptual difference. However, this is unlikely to affect 
filter quality given that neither ‘moderator’ nor ‘predictor’ proved to be sensitive 
keywords. 
 
Third, the search filters need to be tested in other medical domains. However, by 
excluding disease and field-specific keywords in the search filter generation we have 
tried to maximise generalisability. Many keywords in the search filters, such as 
‘randomi*’ or ‘controll*’, seem to be related more to study design rather than 
moderator or predictor-specific analysis. Should specific designs be more prevalent 
in a specific field or time frame, and the performance of our filters may be reduced. 
Testing in other domains and/or time frames (or for instance, testing on the 
MCMASTER CLINICAL HEDGES database or Health Knowledge Refinery) may reveal 
these weaknesses and possibly prompt for amendments of these filter in future. 
 
Conclusions 
The search filters developed within this study can help researchers to identify and 
retrieve papers on moderators or predictors of treatment effects. This represents an 
important step forward in identifying information to facilitate research on stratified or 
personalised health care. 
Acknowledgements 
This study is performed as part ofthe INTEGRATE-HTA project. This is a 3-year 
project co-funded by the European Union under the Seventh Framework Programme 
(FP7-Health-2012-Innovation) under grant agreement number 306141, which aims to 
develop concepts and methods that enable a patient-centred, comprehensive 
 
 
assessment of complex health technologies. The consortium for INTEGRATE-HTA 
comprises seven partners from five different countries and is coordinated by the 
University of Bremen. For much information, visit the website http://www.integrate-
hta.eu. We would like to thank Kristin Bakke Lysdahl for her valuable input during the 
preparation of the manuscript. 
Competing interest 
The authors declare they have no competing interests. 
Funding 
This research was performed as part of the INTEGRATE-HTA project. The 
INTEGRATEHTA Project is cofunded by the European Commission under the 7th 
Framework Programme for Research and Technological Development under grant 
agreement number 306141. The EC had no involvement in the design, collection, 
analysis or interpretation of data or writing the manuscript. 
A┌デｴﾗヴゲげ IﾗﾐデヴｷH┌デｷﾗﾐゲ 
All authors contributed to designing and setting up the research. MT, WK and CL 
performed the data collection. RvH, WK, MT and AB performed the analysis. AB and 
GJvdW contributed additionally to the interpretation of the results and helped 
interpreting the data. All authors reviewed the manuscript, provided feedback and 
read and agreed upon the final manuscript for submission. 
References 
Bachmann, L. M., Coray, R., Estermann, P., & Ter Riet, G. (2002). Identifying diagnostic 
studies in MEDLINE: Reducing the number needed to read. Journal of the American 
Medical Informatics Association, 9(6), 653–658. 
Baron, R. M., & Kenny, D. A. (1986). The moderator-mediator variable distinction in 
social psychological research: Conceptual, strategic, and statistical considerations. 
Journal of Personality and Social Psychology, 51, 1173–1182. 
 
 
Bast, R. C., & Hortobagyi, G. N. (2004). Individualized care for patients with cancer—a 
work in progress. New England Journal of Medicine, 351(27), 2865–2867. 
https://doi.org/doi: 10.1056/NEJMe048300. 
Burgos, P. I., Danila, M. I., Kelley, J. M., Hughes, L. B., & Bridges, S. L. Jr. (2009). 
Understanding personalized medicine in rheumatoid arthritis: A clinician’s guide to 
the future. Therapeutic Advances in Musculoskeletal Disease, 1 (2), 97–105. 
https://doi.org/10.1177/1759720X09351778. 
Chatterley, T., & Dennett, L. (2012). Utilisation of search filters in systematic reviews of 
prognosis questions. Health Information & Libraries Journal, 29(4), 309–322. 
https://doi. org/10.1111/hir.12004. 
Cunningham, D., Pyrhonen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., ... Herait, 
P. (1998). Randomised trial of irinotecan plus supportive care versus supportive care 
alone after fluorouracil failure for patients with metastatic colorectal cancer. The 
Lancet, 352(9138), 1413–1418. https://doi.org/10.1016/S0140-6736(98)02309-5. 
Evans, W. E., & Relling, M. V. (2004). Moving towards individualized medicine with 
pharmacogenomics. Nature, 429(6990), 464–468. 
Gibson, D. S., Rooney, M. E., Finnegan, S., Qiu, J., Thompson, D. C., Labaer, J., ... Duncan, 
M. W. (2012). Biomarkers in rheumatology, now and in the future. Rheumatology 
(Oxford), 51(3), 423–433. https://doi.org/10.1093/rheumatology/ker358. 
Haynes, R. B., McKibbon, K. A., Wilczynski, N. L., Walter, S. D., & Werre, S. R. (2005). 
Optimal search strategies for retrieving scientifically strong studies of treatment 
from Medline: Analytical survey. BMJ, 330, 1179. https://doi.org/ 
10.1136/bmj.38446.498542.8F. 
Haynes, R. B., Wilczynski, N., McKibbon, K. A., Walker, C. J., & Sinclair, J. C. (1994). 
Developing optimal search strategies for detecting clinically sound studies in 
MEDLINE. Journal of the American Medical Informatics Association, 1 (6), 447–458. 
https://doi.org/10.1136/jamia.1994.95153434. 
Hoogendam, A., de Vries Robbe, P. F., Stalenhoef, A. F., & Overbeke, A. J. (2009). 
Evaluation of PubMed filters used for evidence-based searching: Validation using 
 
 
relative recall. Journal of the Medical Library Association, 97(3), 186–193. 
https://doi.org/10.3163/1536-5050.97.3.007. 
Huang, Y., Yang, Z., Wang, J., Zhuo, L., Li, Z., & Zhan, S. (2016). Performance of search 
strategies to retrieve systematic reviews of diagnostic test accuracy from the 
Cochrane Library. Journal of Evidence-Based Medicine, 9, 77–83. 
https://doi.org/10.1111/jebm.12200. 
Jenkins, M. (2004). Evaluation of methodological search filters– a review. Health 
Information & Libraries Journal, 21(3), 148–163. https://doi.org/10.1111/j.1471-
1842.2004.00511.x. 
Kraemer, H. C., Wilson, G. T., Fairburn, C. G., & Agras, W. S. (2002). Mediators and 
moderators of treatment effects in randomized clinical trials. Archives of General 
Psychiatry, 59 (10), 877. 
Kravitz, R. L., Duan, N., & Braslow, J. (2004). Evidence-based medicine, heterogeneity 
of treatment effects, and the trouble with averages. Milbank Quarterly, 82(4), 661–
687. https://d oi.org/10.1111/j.0887-378X.2004.00327.x. 
McKibbon, K. A., Wilczynski, N. L., Haynes, R. B., & Team, H. (2009). Retrieving 
randomized controlled trials from medline: A comparison of 38 published search 
filters. Health Information & Libraries Journal, 26(3), 187–202. https://doi. 
org/10.1111/j.1471-1842.2008.00827.x. 
Shariff, S. Z., Sontrop, J. M., Haynes, R. B., Iansavichus, A. V., McKibbon, K. A., Wilczynski, 
N. L., ... Garg, A. X. (2012). Impact of PubMed search filters on the retrieval of evidence 
by physicians. CMAJ, 184(3), E184–E190. https://d oi.org/10.1503/cmaj.101661. 
White, V. J., Glanville, J. M., Lefebvre, C., & Sheldon, T. A. (2001). A statistical approach 
to designing search filters to find systematic reviews: Objectivity enhances accuracy. 
Journal of Information Science, 27(6), 357–370. https://doi. 
org/10.1177/016555150102700601. 
Wilczynski, N. L., Walker, C. J., McKibbon, K. A., & Haynes, R. B. (1993). Assessment of 
methodologic search filters in MEDLINE. In Proc Annu Symp Comput Appl Med Care, 
pp. 601–605. 
 
 
Received 21 March 2017; Accepted 7 June 2018 
 
 
Appendix A 
Search string 
(“Lancet”[Journal] OR “N Engl J Med”[Journal] OR “Arthritis Care Res 
(Hoboken)”[Journal] OR “Arthritis Rheum”[Journal] OR “Ann Rheum Dis”[Journal] OR 
“Arthritis Res Ther” [Journal]) AND 2011[pdat] NOT 2012[pdat]. 
 
 
Appendix B 
Articles identified as ‘moderators relevant to rheumatology’ (n = 198) during the 
manual search of the six journals for the year 2011 (‘reference set’ subset). 
References 
Abdool Karim, S. S., Naidoo, K., Grobler, A., Padayatchi, N., Baxter, C., Gray, A. L., ... 
Abdool Karim, Q. (2011). Integration of antiretroviral therapy with tuberculosis 
treatment. New England Journal of Medicine, 365(16), 1492– 1501. 
https://doi.org/10.1056/NEJMoa1014181.  
Abraham, W. T., Adamson, P. B., Bourge, R. C., Aaron, M. F., Costanzo, M. R., Stevenson, 
L. W., ... CHAMPION Trial Study Group. (2011). Wireless pulmonary artery 
haemodynamic monitoring in chronic heart failure: A randomised controlled trial. 
The Lancet, 377(9766), 658–666. https://doi.org/10.1016/s0140-6736(11)60101-3. 
Accord Study Group, Gerstein, H. C., Miller, M. E., Genuth, S., Ismail-Beigi, F., Buse, J. 
B., ... Friedewald, W. T. (2011). Long-term effects of intensive glucose lowering on 
cardiovascular outcomes. New England Journal of Medicine, 364(9), 818–828. 
https://doi.org/10.1056/NEJMoa1006524. 
Active I. Investigators, Yusuf, S., Healey, J. S., Pogue, J., Chrolavicius, S., Flather, M., & 
Connolly, S. J. (2011). Irbesartan in patients with atrial fibrillation. New England 
Journal of Medicine, 364(10), 928–938. https://doi.org/10. 
1056/NEJMoa1008816. 
Aim-High Investigators, Boden, W. E., Probstfield, J. L., Anderson, T., Chaitman, B. R., 
Desvignes-Nickens, P., & Weintraub, W. (2011). Niacin in patients with low HDL 
cholesterol levels receiving intensive statin therapy. New England Journal of 
Medicine, 365(24), 2255–2267. https://d oi.org/10.1056/NEJMoa1107579. 
Albert, R. K., Connett, J., Bailey, W. C., Casaburi, R., Cooper, J. A. Jr, Criner, G. J., ... COPD 
Clinical Research Network. (2011). Azithromycin for prevention of exacerbations of 
 
 
COPD. New England Journal of Medicine, 365(8), 689–698. 
https://doi.org/10.1056/NEJMoa1104623. 
Alexander, J. H., Lopes, R. D., James, S., Kilaru, R., He, Y., Mohan, P., ... APPRAISE-2 
Investigators. (2011). Apixaban with antiplatelet therapy after acute coronary 
syndrome. New England Journal of Medicine, 365(8), 699–708. https://doi. 
org/10.1056/NEJMoa1105819. 
Altman, D., Vayrynen, T., Engh, M. E., Axelsen, S., Falconer, C., & Nordic Transvaginal 
Mesh Group. (2011). Anterior colporrhaphy versus transvaginal mesh for pelvic-organ 
prolapse. New England Journal of Medicine, 364(19), 1826– 1836. 
https://doi.org/10.1056/NEJMoa1009521. 
Andrews, R. C., Cooper, A. R., Montgomery, A. A., Norcross, A. J., Peters, T. J., Sharp, D. 
J., ... Dayan, C. M. (2011). Diet or diet plus physical activity versus usual care in patients 
with newly diagnosed type 2 diabetes: The Early ACTID randomised controlled trial. 
The Lancet, 378(9786), 129–139. https://doi.org/10.1016/s0140-6736(11)60442-x. 
Arends, S., Brouwer, E., van der Veer, E., Groen, H., Leijsma, M. K., Houtman, P. M., ... 
Spoorenberg, A. (2011). Baseline predictors of response and discontinuation of tumor 
necrosis factor-alpha blocking therapy in ankylosing spondylitis: A prospective 
longitudinal observational cohort study. Arthritis Research & Therapy, 13(3), R94. 
https://doi. org/10.1186/ar3369. 
Arnold, L. M., Wang, F., Ahl, J., Gaynor, P. J., & Wohlreich, M. M. (2011). Improvement in 
multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: 
Secondary analysis of a randomized, placebo-controlled trial. Arthritis Research & 
Therapy, 13(3), R86. https://doi.org/10. 
1186/ar3359. 
Arora, S., Thornton, K., Murata, G., Deming, P., Kalishman, S., Dion, D., ... Qualls, C. (2011). 
Outcomes of treatment for hepatitis C virus infection by primary care providers. New 
England Journal of Medicine, 364(23), 2199–2207. 
https://doi.org/10.1056/NEJMoa1009370. 
 
 
Arts, E. E., Jansen, T. L., Den Broeder, A., Vonkeman, H. E., Dutmer, E., Van de Laar, M. A., 
... Fransen, J. (2011). Statins inhibit the antirheumatic effects of rituximab in 
rheumatoid arthritis: Results from the Dutch Rheumatoid Arthritis Monitoring 
(DREAM) registry. Annals of the Rheumatic Diseases, 70(5), 877–878. 
https://doi.org/10.1136/ ard.2010.136093. 
Atchia, I., Kane, D., Reed, M. R., Isaacs, J. D., & Birrell, F. (2011). Efficacy of a single 
ultrasound-guided injection for the treatment of hip osteoarthritis. Annals of the 
Rheumatic Diseases, 70(1), 110–116. https://doi.org/10.1136/ard.2009.127183. 
Aufderheide, T. P., Frascone, R. J., Wayne, M. A., Mahoney, B. D., Swor, R. A., Domeier, R. 
M., ... Lurie, K. G. (2011). Standard cardiopulmonary resuscitation versus active 
compression-decompression cardiopulmonary resuscitation with augmentation of 
negative intrathoracic pressure for outof-hospital cardiac arrest: A randomised trial. 
The Lancet, 377(9762), 301–311. https://doi.org/10.1016/s0140-6736(10) 62103-4. 
Aufderheide, T. P., Nichol, G., Rea, T. D., Brown, S. P., Leroux, B. G., Pepe, P. E., ... 
Resuscitation Outcomes Consortium Investigators. (2011). A trial of an impedance 
threshold device in out-of-hospital cardiac arrest. New England Journal of Medicine, 
365(9), 798–806. https://doi. org/10.1056/NEJMoa1010821. 
Bacon, B. R., Gordon, S. C., Lawitz, E., Marcellin, P., Vierling, J. M., Zeuzem, S., ... HCV 
RESPOND-2 Investigators. (2011). Boceprevir for previously treated chronic HCV 
genotype 1 infection. New England Journal of Medicine, 364(13), 1207–1217. 
https://doi.org/10.1056/ NEJMoa1009482. 
Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., ... SHARP 
Investigators. (2011). The effects of lowering LDL cholesterol with simvastatin plus 
ezetimibe in patients with chronic kidney disease (Study of Heart and Renal 
Protection): A randomised placebocontrolled trial. The Lancet, 377(9784), 2181–2192. 
https://d oi.org/10.1016/s0140-6736(11)60739-3. 
Bakker, M. F., Jacobs, J. W., Welsing, P. M., Vreugdenhil, S. A., van Booma-Frankfort, C., 
Linn-Rasker, S. P., ... Utrecht Arthritis Cohort Study Group. (2011). Early clinical 
response to treatment predicts 5-year outcome in RA patients: Followup results from 
 
 
the CAMERA study. Annals of the Rheumatic Diseases, 70(6), 1099–1103. 
https://doi.org/10.1136/ard.2010.137943. 
Banerjee, S., Hellier, J., Dewey, M., Romeo, R., Ballard, C., Baldwin, R., ... Burns, A. (2011). 
Sertraline or mirtazapine for depression in dementia (HTA-SADD): A randomised, 
multicentre, double-blind, placebo-controlled trial. The Lancet, 378(9789), 403–411. 
https://doi.org/10.1016/s01406736(11)60830-1. 
Bari, A., Sadruddin, S., Khan, A., Khan, I., Khan, A., Lehri, I. A., ... Qazi, S. A. (2011). 
Community case management of severe pneumonia with oral amoxicillin in children 
aged 2-59 months in Haripur district, Pakistan: A cluster randomised trial. The Lancet, 
378(9805), 1796–1803. https://doi.org/10.1016/s0140-6736(11)61140-9. 
Becker, M. L., Gaedigk, R., van Haandel, L., Thomas, B., Lasky, A., Hoeltzel, M., ... Leeder, 
J. S. (2011). The effect of genotype on methotrexate polyglutamate variability in 
juvenile idiopathic arthritis and association with drug response. Arthritis and 
Rheumatism, 63(1), 276–285. https://d oi.org/10.1002/art.30080. 
Bednarek, P. H., Creinin, M. D., Reeves, M. F., Cwiak, C., Espey, E., Jensen, J. T., Post-
Aspiration, I. U. D. R. S. T. G. (2011). Immediate versus delayed IUD insertion after 
uterine aspiration. New England Journal of Medicine, 364(23), 2208–2217. 
https://doi.org/10.1056/NEJMoa1011600. 
Belch, J., Hiatt, W. R., Baumgartner, I., Driver, I. V., Nikol, S., Norgren, L., ... TAMARIS 
Committees and Investigators. (2011). Effect of fibroblast growth factor NV1FGF on 
amputation and death: A randomised placebo-controlled trial of gene therapy in 
critical limb ischaemia. The Lancet, 377 (9781), 1929–1937. 
https://doi.org/10.1016/s0140-6736(11) 60394-2. 
Bierma-Zeinstra, S. M., &Verhagen, A. P. (2011). Osteoarthritis 
subpopulations and implications for clinical trial design. Arthritis Research & 
Therapy, 13(2), 213. https://doi.org/10.1186/ar3299. 
Bill-Axelson, A., Holmberg, L., Ruutu, M., Garmo, H., Stark, J. R., Busch, C., ... SPCG-4 
Investigators. (2011). Radical prostatectomy versus watchful waiting in early prostate 
 
 
cancer. New England Journal of Medicine, 364(18), 1708– 1717. 
https://doi.org/10.1056/NEJMoa1011967. 
Blaha, M. J., Budoff, M. J., DeFilippis, A. P., Blankstein, R., Rivera, J. J., Agatston, A., ... Nasir, 
K. (2011). Associations between C-reactive protein, coronary artery calcium, and 
cardiovascular events: Implications for the JUPITER population from MESA, a 
population-based cohort study. The Lancet, 378(9792), 684–692. 
https://doi.org/10.1016/ s0140-6736(11)60784-8. 
Blanc, F. X., Sok, T., Laureillard, D., Borand, L., Rekacewicz, C., Nerrienet, E., ... CAMELIA 
(ANRS 1295-CIPRA KH001) Study Team. (2011). Earlier versus later start of 
antiretroviral therapy in HIV-infected adults with tuberculosis. New England Journal 
of Medicine, 365(16), 1471–1481. https://doi.org/10.1056/NEJMoa1013911. 
Boeckxstaens, G. E., Annese, V., des Varannes, S. B., Chaussade, S., Costantini, M., 
Cuttitta, A., ... European Achalasia Trial Investigators. (2011). Pneumatic dilation 
versus laparoscopic Heller’s myotomy for idiopathic achalasia. New England Journal 
of Medicine, 364(19), 1807– 1816. https://doi.org/10.1056/nejmoa1010502 
Bonow, R. O., Maurer, G., Lee, K. L., Holly, T. A., Binkley, P. F., Desvigne-Nickens, P., 
...STICH Trial Investigators. (2011). Myocardial viability and survival in ischemic left 
ventricular dysfunction. New England Journal of Medicine, 364(17), 1617–1625. 
https://doi.org/10.1056/NEJMoa 1100358. 
Bosello, S., Fedele, A. L., Peluso, G., Gremese, E., Tolusso, B., & Ferraccioli, G. (2011). 
Very early rheumatoid arthritis is the major predictor of major outcomes: Clinical 
ACR remission and radiographic non-progression. Annals of the Rheumatic Diseases, 
70(7), 1292–1295. https://doi.org/10.1136/ard.2010.142729. 
Bousser, M. G., Amarenco, P., Chamorro, A., Fisher, M., Ford, I., Fox, K. M., ... PERFORM 
Study Investigators. (2011). Terutroban versus aspirin in patients with cerebral 
ischaemic events (PERFORM): A randomised, double-blind, parallelgroup trial. The 
Lancet, 377(9782), 2013–2022. https://doi. org/10.1016/s0140-6736(11)60600-4. 
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., ... 
Gynecologic Oncology Group. (2011). Incorporation of bevacizumab in the primary 
 
 
treatment of ovarian cancer. New England Journal of Medicine, 365(26), 2473–
2483. https://doi.org/10.1056/ NEJMoa1104390. 
Burmester, G. R., Feist, E., Kellner, H., Braun, J., IkingKonert, C., & Rubbert-Roth, A. 
(2011). Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab 
after 4 and 24 weeks in patients with active rheumatoid arthritis: The first phase IIIb 
real-life study (TAMARA). Annals of the Rheumatic Diseases, 70(5), 755–759. https://d 
oi.org/10.1136/ard.2010.139725. 
Busse, W. W., Morgan, W. J., Gergen, P. J., Mitchell, H. E., Gern, J. E., Liu, A. H., ... Sorkness, 
C. A. (2011). Randomized trial of omalizumab (anti-IgE) for asthma in inner-city 
children. New England Journal of Medicine, 364 (11), 1005–1015. 
https://doi.org/10.1056/NEJMoa1009705. 
Carson, J. L., Terrin, M. L., Noveck, H., Sanders, D. W., Chaitman, B. R., Rhoads, G. G., ... 
Focus Investigators. (2011). Liberal or restrictive transfusion in high-risk patients 
after hip surgery. New England Journal of Medicine, 365 (26), 2453–2462. 
https://doi.org/10.1056/NEJMoa1012452. 
Casaer, M. P., Mesotten, D., Hermans, G., Wouters, P. J., Schetz, M., Meyfroidt, G., ... Van 
den Berghe, G. (2011). Early versus late parenteral nutrition in critically ill adults. New 
England Journal of Medicine, 365(6), 506–517. 
https://doi.org/10.1056/NEJMoa1102662. 
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., ... BRIM-3 
Study Group. (2011). Improved survival with vemurafenib in melanoma with BRAF 
V600E mutation. New England Journal of Medicine, 364(26), 2507–2516. 
https://doi.org/10.1056/NEJMoa 1103782. 
Chatzidionysiou, K., Lie, E., Nasonov, E., Lukina, G., Hetland, M. L., Tarp, U., ... van 
Vollenhoven, R. F. (2011). Highest clinical effectiveness of rituximab in autoantibody-
positive patients with rheumatoid arthritis and in those for whom no more than one 
previous TNF antagonist has failed: Pooled data from 10 European registries. Annals 
of the Rheumatic Diseases, 70(9), 1575–1580. https://doi.org/10.1136/ard.2010. 
148759. 
 
 
Chen, D. Y., Chen, Y. M., Chen, H. H., Hsieh, C. W., Lin, C. C., & Lan, J. L. (2011). Increasing 
levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with 
an inadequate response to anti-TNF-alpha therapy. Arthritis Research & Therapy, 
13(4), R126. https://doi.org/10.1186/ ar3431. 
Cheng, G., Saleh, M. N., Marcher, C., Vasey, S., Mayer, B., Aivado, M., ... Bussel, J. B. (2011). 
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-
month, randomised, phase 3 study. The Lancet, 377(9763), 393–402. 
https://doi.org/10.1016/s0140-6736(10)60959-2. 
Clowse, M. E., Copland, S. C., Hsieh, T. C., Chow, S. C., Hoffman, G. S., Merkel, P. A., ... 
WGET Research Group. (2011). Ovarian reserve diminished by oral 
cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener’s). 
Arthritis Care & Research, 63(12), 1777–1781. https://doi.org/10.1002/acr.20605. 
Cohen, D. J., Van Hout, B., Serruys, P. W., Mohr, F. W., Macaya, C., den Heijer, P., ... 
Cardiac Surgery Investigator. (2011). Quality of life after PCI with drug-eluting stents 
or coronary-artery bypass surgery. New England Journal of Medicine, 364(11), 1016–
1026. https://doi.org/10.1056/ NEJMoa1001508. 
Coleman, R. E., Marshall, H., Cameron, D., Dodwell, D., Burkinshaw, R., Keane, M., ... 
AZURE Investigators. (2011). Breast-cancer adjuvant therapy with zoledronic acid. 
New England Journal of Medicine, 365(15), 1396–1405. 
https://doi.org/10.1056/NEJMoa1105195. 
Connolly, S. J., Camm, A. J., Halperin, J. L., Joyner, C., Alings, M., Amerena, J., ... PALLAS 
Investigators. (2011). Dronedarone in high-risk permanent atrial fibrillation. New 
England Journal of Medicine, 365(24), 2268–2276. https://d 
oi.org/10.1056/NEJMoa1109867. 
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H. C., Hart, R., Golitsyn, S., ... AVERROES 
Steering Committee and Investigators. (2011). Apixaban in patients with atrial 
fibrillation. New England Journal of Medicine, 364(9), 806– 817. 
https://doi.org/10.1056/NEJMoa1007432. 
 
 
Cooper, W. O., Habel, L. A., Sox, C. M., Chan, K. A., Arbogast, P. G., Cheetham, T. C., ... 
Ray, W. A. (2011). ADHD drugs and serious cardiovascular events in children and young 
adults. New England Journal of Medicine, 365 (20), 1896-1904. 
https://doi.org/10.1056/NEJMoa1110212. 
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., ... 
Matthews, J. G. (2011). Lebrikizumab treatment in adults with asthma. New England 
Journal of Medicine, 365(12), 1088–1098. https://doi.org/10.1056/NEJMoa1106469. 
Cortes, J., O’Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., ... 
EMBRACE Investigators. (2011). Eribulin monotherapy versus treatment of physician’s 
choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label 
randomised study. The Lancet, 377(9769), 914–923. https://doi.org/10.1016/s0140-
6736(11)60070-6.   
Coulthard, L. R., Taylor, J. C., Eyre, S., Biologics in Rheumatoid Arthritis Group 
Genomics, Robinson, J. I., ... McDermott, M. F. (2011). Genetic variants within the MAP 
kinase signalling network and anti-TNF treatment response in rheumatoid arthritis 
patients. Annals of the Rheumatic Diseases, 70(1), 98–103. 
https://doi.org/10.1136/ard.2010. 133249   
Crash-collaborators, Roberts, I., Shakur, H., Afolabi, A., Brohi, K., Coats, T., ... Woolley, T. 
(2011). The importance of early treatment with tranexamic acid in bleeding trauma 
patients: An exploratory analysis of the CRASH-2 randomised controlled trial. The 
Lancet, 377(9771), 1096– 1101, 1101 e1091-1092. https://doi.org/10.1016/s0140-6736 
(11)60278-x 
Cravioto, M. D., Durand-Carbajal, M., Jimenez-Santana, L., Lara-Reyes, P., Seuc, A. H., & 
Sanchez-Guerrero, J. (2011). Efficacy of estrogen plus progestin on menopausal 
symptoms in women with systemic lupus erythematosus: A randomized, double-
blind, controlled trial. Arthritis Care & Research, 63 (12), 1654–1663. 
https://doi.org/10.1002/acr.20608. 
Crowe, S. R., Merrill, J. T., Vista, E. S., Dedeke, A. B., Thompson, D. M., Stewart, S., ... 
James, J. A. (2011). Influenza vaccination responses in human systemic lupus 
 
 
erythematosus: Impact of clinical and demographic features. Arthritis and 
Rheumatism, 63(8), 2396–2406. https://doi.org/ 10.1002/art.30388. 
Cypel, M., Yeung, J. C., Liu, M., Anraku, M., Chen, F., Karolak, W., ... Keshavjee, S. (2011). 
Normothermic ex vivo lung perfusion in clinical lung transplantation. New England 
Journal of Medicine, 364(15), 1431–1440. https://d oi.org/10.1056/NEJMoa1014597. 
Dall’Era, M., Stone, D., Levesque, V., Cisternas, M., & Wofsy, D. (2011). Identification of 
biomarkers that predict response to treatment of lupus nephritis with 
mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care & Research, 63(3), 
351–357. https://doi.org/10.1002/acr.20397. 
DCCT/EDIC Research Group, de Boer, I. H., Sun, W., Cleary, P. A., Lachin, J. M., Molitch, 
M. E., ... Zinman, B. (2011). Intensive diabetes therapy and glomerular filtration rate in 
type 1 diabetes. New England Journal of Medicine, 365(25), 2366–2376. 
https://doi.org/10.1056/nejmoa1111732  
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., ... COU-AA-301 
Investigators. (2011). Abiraterone and increased survival in metastatic prostate 
cancer. New England Journal of Medicine, 364(21), 1995– 2005. 
https://doi.org/10.1056/NEJMoa1014618. 
de Tisi, J., Bell, G. S., Peacock, J. L., McEvoy, A. W., Harkness, W. F., Sander, J. W., & 
Duncan, J. S. (2011). The long-term outcome of adult epilepsy surgery, patterns of 
seizure remission, and relapse: A cohort study. The Lancet, 378(9800), 1388–1395. 
https://doi.org/10.1016/s0140-6736 (11)60890-8. 
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., ... 
ACT Now Study. (2011). Pioglitazone for diabetes prevention in impaired glucose 
tolerance. New England Journal of Medicine, 364(12), 1104–1115. 
https://doi.org/10.1056/NEJMoa 1010949. 
Diaz-Lagares, C., Perez-Alvarez, R., Garcia-Hernandez, F. J., Ayala-Gutierrez, M. M., 
Callejas, J. L., Martinez-Berriotxoa, A., ... BIOGEAS Study Group. (2011). Rates of, and risk 
factors for, severe infections in patients with systemic autoimmune diseases receiving 
 
 
biological agents off-label. Arthritis Research & Therapy, 13(4), R112. https://doi.org/ 
10.1186/ar3397. 
Diener, M. K., Seiler, C. M., Rossion, I., Kleeff, J., Glanemann, M., Butturini, G., ... Buchler, 
M. W. (2011). Efficacy of stapler versus hand-sewn closure after distal 
pancreatectomy (DISPACT): A randomised, controlled multicentre trial. The Lancet, 
377(9776), 1514–1522. https://d oi.org/10.1016/s0140-6736(11)60237-7. 
Dooley, M. A., Jayne, D., Ginzler, E. M., Isenberg, D., Olsen, N. J., Wofsy, D., ... ALMS Group. 
(2011). Mycophenolate versus azathioprine as maintenance therapy for lupus 
nephritis. New England Journal of Medicine, 365(20), 1886– 1895. 
https://doi.org/10.1056/NEJMoa1014460. 
Duncan, P. W., Sullivan, K. J., Behrman, A. L., Azen, S. P., Wu, S. S., Nadeau, S. E., ... Team, 
L. I. (2011). Bodyweight-supported treadmill rehabilitation after stroke. New England 
Journal of Medicine, 364(21), 2026–2036. https://d oi.org/10.1056/NEJMoa1010790. 
Dunlop, D. D., Song, J., Semanik, P. A., Sharma, L., & Chang, R. W. (2011). Physical activity 
levels and functional performance in the osteoarthritis initiative: A graded 
relationship. Arthritis and Rheumatism, 63(1), 127–136. 
https://doi.org/10.1002/art.27760. 
Durnez, A., Vanderschueren, G., Lateur, L., Westhovens, R., & Verschueren, P. (2011). 
Effectiveness of initial treatment allocation based on expert opinion for prevention 
of rapid radiographic progression in daily practice of an early RA cohort. Annals of 
the Rheumatic Diseases, 70(4), 634–637. https://doi.org/10.1136/ard.2010.135319. 
Early Breast Cancer Trialists’ Collaborative Group, Darby, S., McGale, P., Correa, C., 
Taylor, C., Arriagada, R., ... Peto, R. (2011). Effect of radiotherapy after breast-
conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-
analysis of individual patient data for 10,801 women in 17 randomised trials. The 
Lancet, 378(9804), 1707–1716. https://doi.org/10.1016/s0140-6736(11)61629-2 
Early Breast Cancer Trialists’ Collaborative Group, Davies, C., Godwin, J., Gray, R., 
Clarke, M., Cutter, D., ... Peto, R. (2011). Relevance of breast cancer hormone 
receptors and other factors to the efficacy of adjuvant tamoxifen: Patientlevel meta-
 
 
analysis of randomised trials. The Lancet, 378 (9793), 771–784. 
https://doi.org/10.1016/s0140-6736(11) 60993-8 
Emery, P., & Dorner, T. (2011). Optimising treatment in rheumatoid arthritis: A review 
of potential biological markers of response. Annals of the Rheumatic Diseases, 70(12), 
2063–2070. https://doi.org/10.1136/ard.2010.148015. 
Emery, P., Fleischmann, R., van der Heijde, D., Keystone, E. C., Genovese, M. C., 
Conaghan, P. G., ... Rahman, M. U. (2011). The effects of golimumab on radiographic 
progression in rheumatoid arthritis: Results of randomized controlled studies of 
golimumab before methotrexate therapy and golimumab after methotrexate 
therapy. Arthritis and Rheumatism, 63(5), 1200–1210. https://doi.org/10.1002/art. 
30263. 
Feldman, T., Foster, E., Glower, D. D., Kar, S., Rinaldi, M. J., Fail, P. S., ... EVEREST II 
Investigators. (2011). Percutaneous repair or surgery for mitral regurgitation. New 
England Journal of Medicine, 364(15), 1395–1406. https://d 
oi.org/10.1056/NEJMoa1009355. 
Free, C., Knight, R., Robertson, S., Whittaker, R., Edwards, P., Zhou, W., ... Roberts, I. 
(2011). Smoking cessation support delivered via mobile phone text messaging 
(txt2stop): A single-blind, randomised trial. The Lancet, 378(9785), 49–55. 
https://doi.org/10.1016/s0140-6736(11)60701-0. 
Furst, D. E., Pangan, A. L., Harrold, L. R., Chang, H., Reed, G., Kremer, J. M., & Greenberg, 
J. D. (2011). Greater likelihood of remission in rheumatoid arthritis patients treated 
earlier in the disease course: Results from the Consortium of Rheumatology 
Researchers of North America registry. Arthritis Care Res(Hoboken), 63(6), 856–
864. https://doi.org/ 10.1002/acr.20452 
Gabay, C., Bel, M., Combescure, C., Ribi, C., Meier, S., Posfay-Barbe, K., ... H1N1 Study 
Group. (2011). Impact of synthetic and biologic disease-modifying antirheumatic 
drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: A 
prospective, open-label, parallel-cohort, single-center study. Arthritis and 
Rheumatism, 63(6), 1486– 1496. https://doi.org/10.1002/art.30325. 
 
 
Gabay, C., Medinger-Sadowski, C., Gascon, D., Kolo, F., & Finckh, A. (2011). Symptomatic 
effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: A 
randomized, double-blind, placebo-controlled clinical trial at a single center. Arthritis 
and Rheumatism, 63(11), 3383–3391. https://doi.org/10.1002/art.30574. 
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & 
Day, W. W. (2011). Effects of low-dose, controlled-release, phentermine plus 
topiramate combination on weight and associated comorbidities in overweight and 
obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial. The 
Lancet, 377(9774), 1341–1352. https://doi.org/10.1016/s0140-6736(11)60205-5. 
Genovese, M. C., Covarrubias, A., Leon, G., Mysler, E., Keiserman, M., Valente, R., ... Alten, 
R. (2011). Subcutaneous abatacept versus intravenous abatacept: A phase IIIb 
noninferiority study in patients with an inadequate response to methotrexate. 
Arthritis and Rheumatism, 63(10), 2854–2864. https://doi.org/10.1002/art.30463. 
Glazener, C., Boachie, C., Buckley, B., Cochran, C., Dorey, G., Grant, A., ... N’Dow, J. (2011). 
Urinary incontinence in men after formal one-to-one pelvic-floor muscle training 
following radical prostatectomy or transurethral resection of the prostate (MAPS): 
Two parallel randomised controlled trials. The Lancet, 378(9788), 328–337. 
https://doi.org/10.1016/s0140-6736(11)60751-4. 
Glintborg, B., Ostergaard, M., Dreyer, L., Krogh, N. S., Tarp, U., Hansen, M. S., ... Hetland, 
M. L. (2011). Treatment response, drug survival, and predictors thereof in 764 
patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha 
therapy: Results from the nationwide Danish DANBIO registry. Arthritis and 
Rheumatism, 63(2), 382–390. https://doi.org/10.1002/art.30117. 
Gopel, W., Kribs, A., Ziegler, A., Laux, R., Hoehn, T., Wieg, C., ... German Neonatal, N. 
(2011). Avoidance of mechanical ventilation by surfactant treatment of spontaneously 
breathing preterm infants (AMV): An openlabel, randomised, controlled trial. The 
Lancet, 378(9803), 1627–1634. https://doi.org/10.1016/s0140-6736(11)60986-0. 
Goss, P. E., Ingle, J. N., Ales-Martinez, J. E., Cheung, A. M., Chlebowski, R. T., Wactawski-
Wende, J., ... NCIC CTG MAP.3 Study Investigators. (2011). Exemestane for breast 
 
 
cancer prevention in postmenopausal women. New England Journal of Medicine, 
364(25), 2381–2391. https://doi.org/10. 
1056/NEJMoa1103507. 
Granger, C. B., Alexander, J. H., McMurray, J. J., Lopes, R. D., Hylek, E. M., Hanna, M., ... 
ARISTOTLE Committees and Investigators. (2011). Apixaban versus warfarin in 
patients with atrial fibrillation. New England Journal of Medicine, 365(11), 981–992. 
https://doi.org/10.1056/NEJMoa 1107039. 
Greenberg, E. R., Anderson, G. L., Morgan, D. R., Torres, J., Chey, W. D., Bravo, L. E., ... 
Baker, L. H. (2011). 14-day triple, 5-day concomitant, and 10-day sequential therapies 
for Helicobacter pylori infection in seven Latin American sites: A randomised trial. 
The Lancet, 378(9790), 507–514. https://doi.org/10.1016/s0140-6736(11)60825-8. 
Griffin, S. J., Borch-Johnsen, K., Davies, M. J., Khunti, K., Rutten, G. E., Sandbaek, A., ... 
Lauritzen, T. (2011). Effect of early intensive multifactorial therapy on 5-year 
cardiovascular outcomes in individuals with type 2 diabetes detected by screening 
(ADDITION-Europe): A cluster randomised trial. The Lancet, 378(9786), 156–167. 
https://d oi.org/10.1016/s0140-6736(11)60698-3. 
Haller, H., Ito, S., Izzo, J. L. Jr, Januszewicz, A., Katayama, S., Menne, J., ... ROADMAP Trial 
Investigators. (2011). Olmesartan for the delay or prevention of microalbuminuria in 
type 2 diabetes. New England Journal of Medicine, 364 (10), 907–917. 
https://doi.org/10.1056/NEJMoa1007994. 
Hasija, R., Pistorio, A., Ravelli, A., Demirkaya, E., Khubchandani, R., Guseinova, D., ... 
Pediatric Rheumatology International Trials Organization. (2011). Therapeutic 
approaches in the treatment of juvenile dermatomyositis in patients with recent-
onset disease and in those experiencing disease flare: An international multicenter 
PRINTO study. Arthritis and Rheumatism, 63(10), 3142–3152. 
https://doi.org/10.1002/art.30475. 
Havlir, D. V., Kendall, M. A., Ive, P., Kumwenda, J., Swindells, S., Qasba, S. S., ... AIDS 
Clinical Trials Group Study A5221. (2011). Timing of antiretroviral therapy for HIV-1 
 
 
infection and tuberculosis. New England Journal of Medicine, 365(16), 1482–1491. 
https://doi.org/10.1056/ NEJMoa1013607. 
Heart Protection Study Collaborative Group, Bulbulia, R., Bowman, L., Wallendszus, K., 
Parish, S., Armitage, J., ... Collins, R. (2011). Effects on 11-year mortality and morbidity 
of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk 
individuals: A randomised controlled trial. The Lancet, 378(9808), 2013–2020. 
https://d oi.org/10.1016/s0140-6736(11)61125-2 
Herbst, R. S., Ansari, R., Bustin, F., Flynn, P., Hart, L., Otterson, G. A., ... Hainsworth, J. 
(2011). Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-
small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): A 
double-blind, placebo-controlled, phase 3 trial. The Lancet, 377(9780), 1846–1854. 
https://doi.org/10.1016/s0140-6736(11)60545-x. 
Hill, J. C., Whitehurst, D. G., Lewis, M., Bryan, S., Dunn, K. M., Foster, N. E., ... Hay, E. M. 
(2011). Comparison of stratified primary care management for low back pain with 
current best practice (STarT Back): A randomised controlled trial. The Lancet, 
378(9802), 1560–1571. https://doi.org/10.1016/s0140-6736(11)60937-9. 
Hinks, A., Moncrieffe, H., Martin, P., Ursu, S., Lal, S., Kassoumeri, L., ... Thomson, W. 
(2011). Association of the 5-aminoimidazole-4-carboxamide ribonucleotide 
transformylase gene with response to methotrexate in juvenile idiopathic arthritis. 
Annals of the Rheumatic Diseases, 70(8), 1395–1400. https://doi.org/10.1136/ard.2010. 
146191. 
Hoberman, A., Paradise, J. L., Rockette, H. E., Shaikh, N., Wald, E. R., Kearney, D. H., ... 
Barbadora, K. A. (2011). Treatment of acute otitis media in children under 2 years of 
age. New England Journal of Medicine, 364(2), 105–115. 
https://doi.org/10.1056/NEJMoa0912254. 
Inis Collaborative Group, Brocklehurst, P., Farrell, B., King, A., Juszczak, E., Darlow, B., ... 
Tarnow-Mordi, W. (2011). Treatment of neonatal sepsis with intravenous immune 
globulin. New England Journal of Medicine, 365(13), 1201– 1211. 
https://doi.org/10.1056/nejmoa1100441 
 
 
Jacobson, I. M., McHutchison, J. G., Dusheiko, G., Di Bisceglie, A. M., Reddy, K. R., Bzowej, 
N. H., ... ADVANCE Study Team. (2011). Telaprevir for previously untreated chronic 
hepatitis C virus infection. New England Journal of Medicine, 364(25), 2405–2416. 
https://doi.org/10.1056/NEJMoa1012912. 
Jamnitski, A., Bartelds, G. M., Nurmohamed, M. T., van Schouwenburg, P. A., van 
Schaardenburg, D., Stapel, S. O., ... Wolbink, G. J. (2011). The presence or absence of 
antibodies to infliximab or adalimumab determines the outcome of switching to 
etanercept. Annals of the Rheumatic Diseases, 70(2), 284–288. 
https://doi.org/10.1136/ard.2010.135111. 
Jolly, S. S., Yusuf, S., Cairns, J., Niemela, K., Xavier, D., Widimsky, P., ... RIVAL Trial Group. 
(2011). Radial versus femoral access for coronary angiography and intervention in 
patients with acute coronary syndromes (RIVAL): A randomised, parallel group, 
multicentre trial. The Lancet, 377 (9775), 1409–1420. https://doi.org/10.1016/s0140-
6736(11) 60404-2. 
Jones, C. U., Hunt, D., McGowan, D. G., Amin, M. B., Chetner, M. P., Bruner, D. W., ... 
Shipley, W. U. (2011). Radiotherapy and short-term androgen deprivation for localized 
prostate cancer. New England Journal of Medicine, 365(2), 107–118. 
https://doi.org/10.1056/NEJMoa1012348.  
Jozwiak, M., Oude Rengerink, K., Benthem, M., van Beek, E., Dijksterhuis, M. G., de Graaf, 
I. M., ... Group, P. S. (2011). Foley catheter versus vaginal prostaglandin E2 gel for 
induction of labour at term (PROBAAT trial): An open-label, randomised controlled 
trial. The Lancet, 378 (9809), 2095–2103. https://doi.org/10.1016/s0140-6736(11) 
61484-0 
Kapetanovic, M. C., Roseman, C., Jonsson, G., Truedsson, L., Saxne, T., & Geborek, P. 
(2011). Antibody response is reduced following vaccination with 7-valent conjugate 
pneumococcal vaccine in adult methotrexate-treated patients with established 
arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis and 
Rheumatism, 63(12), 3723–3732. https://doi.org/10.1002/art.30580.  
 
 
Kastrati, A., Neumann, F. J., Schulz, S., Massberg, S., Byrne, R. A., Ferenc, M., ... ISAR-
REACT 4 Trial Investigators. (2011). Abciximab and heparin versus bivalirudin for 
nonST-elevation myocardial infarction. New England Journal of Medicine, 365(21),
 1980–1989. https://doi.org/10.1056/ NEJMoa1109596. 
Kelley, G. A., Kelley, K. S., Hootman, J. M., & Jones, D. L. (2011). Effects of community-
deliverable exercise on pain and physical function in adults with arthritis and other 
rheumatic diseases: A meta-analysis. Arthritis Care & Research, 63(1), 79–93. 
https://doi.org/10.1002/acr.20347. 
Klaasen, R., Wijbrandts, C. A., Gerlag, D. M., & Tak, P. P. (2011). Body mass index and 
clinical response to infliximab in rheumatoid arthritis. Arthritis and Rheumatism, 
63(2), 359–364. https://doi.org/10.1002/art.30136. 
Klarenbeek, N. B., van der Kooij, S. M., Guler-Yuksel, M., van Groenendael, J. H., Han, K. 
H., Kerstens, P. J., ... Allaart, C. F. (2011). Discontinuing treatment in patients with 
rheumatoid arthritis in sustained clinical remission: Exploratory analyses from the 
BeSt study. Annals of the Rheumatic Diseases, 70(2), 315–319. https://doi.org/10.1136/ 
ard.2010.136556. 
Koike, T., Harigai, M., Inokuma, S., Ishiguro, N., Ryu, J., Takeuchi, T., ... Yamanaka, H. 
(2011). Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: 
Interim analysis of 3881 patients. Annals of the Rheumatic Diseases, 70(12), 2148–2151. 
https://doi.org/10.1136/ard.2011.151092. 
Korswagen, L. A., Bartelds, G. M., Krieckaert, C. L., Turkstra, F., Nurmohamed, M. T., van 
Schaardenburg, D., ... Wolbink, G. J. (2011). Venous and arterial thromboembolic 
events in adalimumab-treated patients with antiadalimumab antibodies: A case 
series and cohort study. Arthritis and Rheumatism, 63(4), 877–883. 
https://doi.org/10.1002/art.30209. 
Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. 
(2011). Injectable extended-release naltrexone for opioid dependence: A double-
blind, placebo-controlled, multicentre randomised trial. The Lancet, 377(9776), 
1506–1513. https://doi.org/10.1016/s0140-6736(11)60358-9. 
 
 
Kume, K., Amano, K., Yamada, S., Hatta, K., Kuwaba, N., & Ohta, H. (2011). Very early 
improvements in the wrist and hand assessed by power Doppler sonography 
predicting later favorable responses in tocilizumab-treated patients with rheumatoid 
arthritis. Arthritis Care & Research, 63(10), 1477–1481. 
https://doi.org/10.1002/acr.20537. 
Lal, P., Su, Z., Holweg, C. T., Silverman, G. J., Schwartzman, S., Kelman, A., ... Townsend, 
M. J. (2011). Inflammation and autoantibody markers identify rheumatoid arthritis 
patients with enhanced clinical benefit following rituximab treatment. Arthritis and 
Rheumatism, 63(12), 3681–3691. https://doi.org/10.1002/art.30596. 
Le Guenno, G., Mahr, A., Pagnoux, C., Dhote, R., Guillevin, L., French Vasculitis Study 
Group. (2011). Incidence and predictors of urotoxic adverse events in 
cyclophosphamide treated patients with systemic necrotizing vasculitides. Arthritis 
and Rheumatism, 63(5), 1435–1445. https://doi.org/ 10.1002/art.30296. 
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., ... OPT-80-003 
Clinical Study Group. (2011). Fidaxomicin versus vancomycin for Clostridium difficile 
infection. New England Journal of Medicine, 364(5), 422–431. 
https://doi.org/10.1056/NEJMoa 0910812. 
Lowenberg, B., Pabst, T., Vellenga, E., van Putten, W., Schouten, H. C., Graux, C., ... Swiss 
Group for Clinical Cancer Research (SAKK) Collaborative Group. (2011). Cytarabine 
dose for acute myeloid leukemia. New England Journal of Medicine, 364(11), 1027–
1036. https://doi.org/10.1056/NEJMoa1010222. 
Maitland, K., Kiguli, S., Opoka, R. O., Engoru, C., OlupotOlupot, P., Akech, S. O., ... FEAST 
Trial Group. (2011). Mortality after fluid bolus in African children with severe 
infection. New England Journal of Medicine, 364(26), 2483– 2495. 
https://doi.org/10.1056/NEJMoa1101549. 
Martineau, A. R., Timms, P. M., Bothamley, G. H., Hanifa, Y., Islam, K., Claxton, A. P., ... 
Griffiths, C. J. (2011). Highdose vitamin D(3) during intensive-phase antimicrobial 
treatment of pulmonary tuberculosis: A double-blind randomised controlled trial. 
The Lancet, 377(9761), 242–250. https://doi.org/10.1016/s0140-6736(10)61889-2. 
 
 
Mathian, A., Devilliers, H., Krivine, A., Costedoat-Chalumeau, N., Haroche, J., Huong, D. 
B., ... Amoura, Z. (2011). Factors influencing the efficacy of two injections of a 
pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus 
erythematosus. Arthritis and Rheumatism, 63(11), 3502–3511. 
https://doi.org/10.1002/art.30576. 
Matucci-Cerinic, M., Denton, C. P., Furst, D. E., Mayes, M. D., Hsu, V. M., Carpentier, P., 
... Seibold, J. R. (2011). Bosentan treatment of digital ulcers related to systemic 
sclerosis: Results from the RAPIDS-2 randomised, double-blind, placebocontrolled 
trial. Annals of the Rheumatic Diseases, 70(1), 32– 38. 
https://doi.org/10.1136/ard.2010.130658. 
Maughan, T. S., Adams, R. A., Smith, C. G., Meade, A. M., Seymour, M. T., Wilson, R. H., & 
MRC COIN Trial Investigators. (2011). Addition of cetuximab to oxaliplatinbased first-
line combination chemotherapy for treatment of advanced colorectal cancer: Results 
of the randomised phase 3 MRC COIN trial. The Lancet, 377(9783), 2103–2114. 
https://doi.org/10.1016/s0140-6736(11)60613-2. 
Mehilli, J., Pache, J., Abdel-Wahab, M., Schulz, S., Byrne, R. A., Tiroch, K., & Is Drug-
Eluting-Stenting Associated with Improved Results in Coronary Artery Bypass Grafts 
Investigators. (2011). Drug-eluting versus bare-metal stents in saphenous vein graft 
lesions (ISAR-CABG): A randomised controlled superiority trial. The Lancet, 
378(9796), 1071– 1078. https://doi.org/10.1016/s0140-6736(11)61255-5. 
Michaud, K., Wallenstein, G., & Wolfe, F. (2011). Treatment and nontreatment 
predictors of health assessment questionnaire disability progression in rheumatoid 
arthritis: A longitudinal study of 18,485 patients. Arthritis Care & Research, 63(3), 
366–372. https://doi.org/10.1002/acr.20405. 
Micu, M. C., Micu, R., & Ostensen, M. (2011). Luteinized unruptured follicle syndrome 
increased by inactive disease and selective cyclooxygenase 2 inhibitors in women 
with inflammatory arthropathies. Arthritis Care & Research, 63 (9), 1334–1338. 
https://doi.org/10.1002/acr.20510. 
 
 
Middleton, S., McElduff, P., Ward, J., Grimshaw, J. M., Dale, S., D’Este, C., ... QASC 
Trialists Group. (2011). Implementation of evidence-based treatment protocols to 
manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (QASC): 
A cluster randomised controlled trial. The Lancet, 378(9804), 1699–1706. 
https://doi.org/10.1016/s0140-6736(11)61485-2. 
Molyneux, E., Nizami, S. Q., Saha, S., Huu, K. T., Azam, M., Bhutta, Z. A., ... CSF 5 Study 
Group. (2011). 5 versus 10 days of treatment with ceftriaxone for bacterial meningitis 
in children: A double-blind randomised equivalence study. The Lancet, 377(9780), 
1837–1845. https://doi.org/10.1016/ s0140-6736(11)60580-1. 
Montalescot, G., Zeymer, U., Silvain, J., Boulanger, B., Cohen, M., Goldstein, P., ... ATOLL 
Investigator. (2011). Intravenous enoxaparin or unfractionated heparin in primary 
percutaneous coronary intervention for ST-elevation myocardial infarction: The 
international randomised openlabel ATOLL trial. The Lancet, 378(9792), 693–703. 
https://doi.org/10.1016/s0140-6736(11)60876-3. 
Musallam, K. M., Tamim, H. M., Richards, T., Spahn, D. R., Rosendaal, F. R., Habbal, A., ... 
Jamali, F. R. (2011). Preoperative anaemia and postoperative outcomes in noncardiac 
surgery: A retrospective cohort study. The Lancet, 378(9800), 1396–1407. 
https://doi.org/10.1016/s0140-6736 (11)61381-0. 
Navarra, S. V., Guzman, R. M., Gallacher, A. E., Hall, S., Levy, R. A., Jimenez, R. E., ... BLISS-
52 Study Group. (2011). Efficacy and safety of belimumab in patients with active 
systemic lupus erythematosus: A randomised, placebocontrolled, phase 3 trial. The 
Lancet, 377(9767), 721–731. https://doi.org/10.1016/s0140-6736(10)61354-2. 
Nguyen-Khac, E., Thevenot, T., Piquet, M. A., Benferhat, S., Goria, O., Chatelain, D., ... 
Group, A.-N. S. (2011). Glucocorticoids plus N-acetylcysteine in severe alcoholic 
hepatitis. New England Journal of Medicine, 365(19), 1781– 1789. 
https://doi.org/10.1056/nejmoa1101214 
Nicholls, S. J., Ballantyne, C. M., Barter, P. J., Chapman, M. J., Erbel, R. M., Libby, P., ... 
Nissen, S. E. (2011). Effect of two intensive statin regimens on progression of coronary 
 
 
disease. New England Journal of Medicine, 365(22), 2078– 2087. 
https://doi.org/10.1056/NEJMoa1110874.  
Nigrovic, P. A., Mannion, M., Prince, F. H., Zeft, A., Rabinovich, C. E., van Rossum, M. A., ... 
Higgins, G. C. (2011). Anakinra as first-line disease-modifying therapy in systemic 
juvenile idiopathic arthritis: Report of forty-six patients from an international 
multicenter series. Arthritis and Rheumatism, 63(2), 545–555. 
https://doi.org/10.1002/art.30128. 
O’Connor, C. M., Starling, R. C., Hernandez, A. F., Armstrong, P. W., Dickstein, K., 
Hasselblad, V., ... Califf, R. M. (2011). Effect of nesiritide in patients with acute 
decompensated heart failure. New England Journal of Medicine, 365(1), 32–43. 
https://doi.org/10.1056/NEJMoa 1100171. 
Okuyama, A., Nagasawa, H., Suzuki, K., Kameda, H., Kondo, H., Amano, K., & Takeuchi, T. 
(2011). Fcgamma receptor IIIb polymorphism and use of glucocorticoids at baseline are 
associated with infusion reactions to infliximab in patients with rheumatoid arthritis. 
Annals of the Rheumatic Diseases, 70(2), 299–304. 
https://doi.org/10.1136/ard.2010.136283. 
Park, S. J., Kim, Y. H., Park, D. W., Yun, S. C., Ahn, J. M., Song, H. G., ... Seung, K. B. (2011). 
Randomized trial of stents versus bypass surgery for left main coronary artery 
disease. New England Journal of Medicine, 364(18), 1718– 1727. 
https://doi.org/10.1056/NEJMoa1100452. 
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., ... ROCKET AF 
Investigators. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. 
New England Journal of Medicine, 365(10), 883–891. 
https://doi.org/10.1056/NEJMoa1009638. 
Pavel, M. E., Hainsworth, J. D., Baudin, E., Peeters, M., Horsch, D., Winkler, R. E., ... 
RADIANT-2 Study Group. (2011). Everolimus plus octreotide long-acting repeatable 
for the treatment of advanced neuroendocrine tumours associated with carcinoid 
syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. The 
Lancet, 378(9808), 2005–2012. https://doi.org/10.1016/s0140-6736(11)61742-x. 
 
 
Pedersen, S. J., Sorensen, I. J., Garnero, P., Johansen, J. S., Madsen, O. R., Tvede, N., ... 
Ostergaard, M. (2011). ASDAS, BASDAI and different treatment responses and their 
relation to biomarkers of inflammation, cartilage and bone turnover in patients with 
axial spondyloarthritis treated with TNFalpha inhibitors. Annals of the Rheumatic 
Diseases, 70(8), 1375–1381. https://doi.org/10.1136/ard.2010.138883. 
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, 
G., ... ICON7 Investigators. (2011). A phase 3 trial of bevacizumab in ovarian cancer. 
New England Journal of Medicine, 365(26), 2484–2496. 
https://doi.org/10.1056/NEJMoa1103799. 
Perruccio, A. V., Davis, A. M., Hogg-Johnson, S., & Badley, E. M. (2011). Importance of 
self-rated health and mental well-being in predicting health outcomes following total 
joint replacement surgery for osteoarthritis. Arthritis Care & Research, 63(7), 973–
981. https://doi.org/10.1002/acr.20467. 
Plant, D., Bowes, J., Potter, C., Hyrich, K. L., Morgan, A. W., Wilson, A. G., ... Barton, A. 
(2011). Genome-wide association study of genetic predictors of anti-tumor necrosis 
factor treatment efficacy in rheumatoid arthritis identifies associations with 
polymorphisms at seven loci. Arthritis and Rheumatism, 63(3), 645–653. 
https://doi.org/10.1002/art.30130. 
Pontifex, E. K., Gerlag, D. M., Gogarty, M., Vinkenoog, M., Gibbs, A., Burgman, I., ... 
FitzGerald, O. (2011). Change in CD3 positive T-cell expression in psoriatic arthritis 
synovium correlates with change in DAS28 and magnetic resonance imaging synovitis 
scores following initiation of biologic therapy–a single centre, open-label study. 
Arthritis Research & Therapy, 13(1), R7. https://doi.org/10.1186/ar3228. 
Poordad, F., McCone, J. Jr, Bacon, B. R., Bruno, S., Manns, M. P., Sulkowski, M. S., ... 
SPRINT-2 Investigators. (2011). Boceprevir for untreated chronic HCV genotype 1 
infection. New England Journal of Medicine, 364(13), 1195–1206. 
https://doi.org/10.1056/NEJMoa1010494. 
Price, D., Musgrave, S. D., Shepstone, L., Hillyer, E. V., Sims, E. J., Gilbert, R. F., ... Harvey, 
I. (2011). Leukotriene antagonists as first-line or add-on asthma-controller therapy. 
 
 
New England Journal of Medicine, 364(18), 1695–1707. 
https://doi.org/10.1056/NEJMoa1010846. 
Prieto-Alhambra, D., Javaid, M. K., Judge, A., Maskell, J., Kiran, A., de Vries, F., ... Arden, 
N. K. (2011). Fracture risk before and after total hip replacement in patients with 
osteoarthritis: Potential benefits of bisphosphonate use. Arthritis and Rheumatism, 
63(4), 992–1001. https://doi.org/ 10.1002/art.30214. 
Prieto-Alhambra, D., Javaid, M. K., Maskell, J., Judge, A., Nevitt, M., Cooper, C., & Arden, 
N. K. (2011). Changes in hip fracture rate before and after total knee replacement due 
to osteoarthritis: A population-based cohort study. Annals of the Rheumatic Diseases, 
70(1), 134–138. https://doi.org/10.1136/ard.2010.131110. 
Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of 
Observational HIV Epidemiological Research Europe (COHERE), Castro, H., Judd, A., 
Gibb, D. M., Butler, K., Lodwick, R. K., ... Phillips, A. (2011). Risk of triple-class virological 
failure in children with HIV: A retrospective cohort study. The Lancet, 377(9777), 
1580– 1587. https://doi.org/10.1016/s0140-6736(11)60208-0 
Quartier, P., Allantaz, F., Cimaz, R., Pillet, P., Messiaen, C., Bardin, C., ... Pascual, V. (2011). 
A multicentre, randomised, double-blind, placebo-controlled trial with the 
interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile 
idiopathic arthritis (ANAJIS trial). Annals of the Rheumatic Diseases, 70(5), 747-754. 
https://d oi.org/10.1136/ard.2010.134254. 
Quoix, E., Zalcman, G., Oster, J. P., Westeel, V., Pichon, E., ... Lavole, A., Intergroupe 
Francophone de Cancerologie Thoracique. (2011). Carboplatin and weekly paclitaxel 
doublet chemotherapy compared with monotherapy in elderly patients with 
advanced non-small-cell lung cancer: IFCT0501 randomised, phase 3 trial. The Lancet, 
378(9796), 1079–1088. https://doi.org/10.1016/s0140-6736(11)60780-0. 
Rahman, N. M., Maskell, N. A., West, A., Teoh, R., Arnold, A., Mackinlay, C., ... Davies, R. J. 
(2011). Intrapleural use of tissue plasminogen activator and DNase in pleural infection. 
New England Journal of Medicine, 365(6), 518– 526. https://doi.org/10.1056/N 
EJMoa1012740. 
 
 
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Drevinek, P., ... Group, V. 
X. S. (2011). A CFTR potentiator in patients with cystic fibrosis and the G551D 
mutation. New England Journal of Medicine, 365(18), 1663– 1672. 
https://doi.org/10.1056/nejmoa1105185 
Raymond, E., Dahan, L., Raoul, J. L., Bang, Y. J., Borbath, I., Lombard-Bohas, C., ... 
Ruszniewski, P. (2011). Sunitinib malate for the treatment of pancreatic 
neuroendocrine tumors. New England Journal of Medicine, 364(6), 501–513. 
https://doi.org/10.1056/NEJMoa1003825. 
Raynauld, J. P., Martel-Pelletier, J., Haraoui, B., Choquette, D., Dorais, M., Wildi, L. M., ... 
Canadian Licofelone Study Group. (2011). Risk factors predictive of joint replacement 
in a 2-year multicentre clinical trial in knee osteoarthritis using MRI: Results from 
over 6 years of observation. Annals of the Rheumatic Diseases, 70(8), 1382-1388. 
https://doi.org/10.1136/ard.2010.146407. 
Recher, C., Coiffier, B., Haioun, C., Molina, T. J., Ferme, C., Casasnovas, O., ... Groupe 
d’Etude des Lymphomes de l’Adulte. (2011). Intensified chemotherapy with ACVBP 
plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse 
large B-cell lymphoma (LNH03-2B): An open-label randomised phase 3 trial. The 
Lancet, 378(9806), 1858–1867. https://doi.org/10.1016/s0140-6736(11)61040-4. 
Rendas-Baum, R., Wallenstein, G. V., Koncz, T., Kosinski, M., Yang, M., Bradley, J., & 
Zwillich, S. H. (2011). Evaluating the efficacy of sequential biologic therapies for 
rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-
alpha inhibitors. Arthritis Research & Therapy, 13(1), R25. 
https://doi.org/10.1186/ar3249. 
Rini, B. I., Escudier, B., Tomczak, P., Kaprin, A., Szczylik, C., Hutson, T. E., ... Motzer, R. J. 
(2011). Comparative effectiveness of axitinib versus sorafenib in advanced renal cell 
carcinoma (AXIS): A randomised phase 3 trial. The Lancet, 378(9807), 1931–1939. 
https://doi.org/10.1016/ s0140-6736(11)61613-9. 
Robert, C., Thomas, L., Bondarenko, I., O’Day, S., M, D. J., Garbe, C., ... Wolchok, J. D. 
(2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. 
 
 
New England Journal of Medicine, 364(26), 2517–2526. 
https://doi.org/10.1056/nejmoa1104621 
Roth, M. D., Tseng, C. H., Clements, P. J., Furst, D. E., Tashkin, D. P., Goldin, J. G., ... 
Scleroderma Lung Study Research Group. (2011). Predicting treatment outcomes 
and responder subsets in scleroderma-related interstitial lung disease. Arthritis and 
Rheumatism, 63(9), 2797–2808. https://doi.org/10.1002/art.30438. 
Rothwell, P. M., Fowkes, F. G., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011). 
Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual 
patient data from randomised trials. The Lancet, 377(9759), 31–41. 
https://doi.org/10.1016/s0140-6736(10) 62110-1. 
Saevarsdottir, S., Wallin, H., Seddighzadeh, M., Ernestam, S., Geborek, P., Petersson, I. 
F., ... SWEFOT Trial Investigators Group. (2011). Predictors of response to methotrexate 
in early DMARD naive rheumatoid arthritis: Results from the initial open-label phase of 
the SWEFOT trial. Annals of the Rheumatic Diseases, 70(3), 469–475. 
https://doi.org/10.1136/ard.2010.139212. 
Saevarsdottir, S., Wedren, S., Seddighzadeh, M., Bengtsson, C., Wesley, A., Lindblad, S., 
... Klareskog, L. (2011). Patients with early rheumatoid arthritis who smoke are less 
likely to respond to treatment with methotrexate and tumor necrosis factor 
inhibitors: Observations from the Epidemiological Investigation of Rheumatoid 
Arthritis and the Swedish Rheumatology Register cohorts. Arthritis and Rheumatism, 
63(1), 26–36. https://doi.org/10.1002/art.27758. 
Salles, G., Seymour, J. F., Offner, F., Lopez-Guillermo, A., Belada, D., Xerri, L., ... Tilly, H. 
(2011). Rituximab maintenance for 2 years in patients with high tumour burden 
follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, 
randomised controlled trial. The Lancet, 377(9759), 4251. https://doi.org/10.1016/ 
s0140-6736(10)62175-7. 
Salmon-Ceron, D., Tubach, F., Lortholary, O., Chosidow, O., Bretagne, S., Nicolas, N., ... 
RATIO group. (2011). Drug specific risk of non-tuberculosis opportunistic infections 
in patients receiving anti-TNF therapy reported to the 3-year prospective French 
 
 
RATIO registry. Annals of the Rheumatic Diseases, 70(4), 616–623. 
https://doi.org/10.1136/ard.2010.137422. 
Samandari, T., Agizew, T. B., Nyirenda, S., Tedla, Z., Sibanda, T., Shang, N., ... Wells, C. D. 
(2011). 6-month versus 36 month isoniazid preventive treatment for tuberculosis in 
adults with HIV infection in Botswana: A randomised, double-blind, placebo-
controlled trial. The Lancet, 377(9777), 1588–1598. https://doi.org/10.1016/s0140-
6736(11)60204-3. 
Sandset, E. C., Bath, P. M., Boysen, G., Jatuzis, D., Korv, J., Luders, S., ... Group, S. S. (2011). 
The angiotensin-receptor blocker candesartan for treatment of acute stroke 
(SCAST): A randomised, placebo-controlled, double-blind trial. The Lancet, 
377(9767), 741–750. https://doi.org/10.1016/s01406736(11)60104-9 
Schwartzentruber, D. J., Lawson, D. H., Richards, J. M., Conry, R. M., Miller, D. M., 
Treisman, J., ... Hwu, P. (2011). gp100 peptide vaccine and interleukin-2 in patients 
with advanced melanoma. New England Journal of Medicine, 364(22), 2119–
2127. https://doi.org/10.1056/ NEJMoa1012863. 
Sellam, J., Hendel-Chavez, H., Rouanet, S., Abbed, K., Combe, B., Le Loet, X., ... Mariette, 
X. (2011). B cell activation biomarkers as predictive factors for the response to 
rituximab in rheumatoid arthritis: A six-month, national, multicenter, open-label 
study. Arthritis and Rheumatism, 63(4), 933–938. https://doi.org/10.1002/art.30233. 
Sellam, J., Rouanet, S., Hendel-Chavez, H., Abbed, K., Sibilia, J., Tebib, J., ... Taoufik, Y. 
(2011). Blood memory B cells are disturbed and predict the response to rituximab in 
patients with rheumatoid arthritis. Arthritis and Rheumatism, 63(12), 3692–3701. 
https://doi.org/10.1002/art.30599. 
Seymour, M. T., Thompson, L. C., Wasan, H. S., Middleton, G., Brewster, A. E., Shepherd, 
S. F., ... National Cancer Research Institute Colorectal Cancer Clinical Studies Group. 
(2011). Chemotherapy options in elderly and frail patients with metastatic colorectal 
cancer (MRC FOCUS2): An openlabel, randomised factorial trial. The Lancet, 
377(9779), 1749–1759. https://doi.org/10.1016/s0140-6736(11)60399-1. 
 
 
Sherman, K. E., Flamm, S. L., Afdhal, N. H., Nelson, D. R., Sulkowski, M. S., Everson, G. T., 
... ILLUMINATE Study Team. (2011). Response-guided telaprevir combination 
treatment for hepatitis C virus infection. New England Journal of Medicine, 365(11), 
1014–1024. https://doi.org/10.1056/NEJMoa1014463. 
Sherry, N., Hagopian, W., Ludvigsson, J., Jain, S. M., Wahlen, J., Ferry, R. J. Jr, ... Protege 
Trial Investigator. (2011). Teplizumab for treatment of type 1 diabetes (Protege 
study): 1-year results from a randomised, placebo-controlled trial. The Lancet, 
378(9790), 487–497. https://doi.org/10.1016/ s0140-6736(11)60931-8. 
Silber, S., Windecker, S., Vranckx, P., Serruys, P. W., & RESOLUTE All Comers 
investigators. (2011). Unrestricted randomised use of two new generation drug-
eluting coronary stents: 2-year patient-related versus stent-related outcomes from 
the RESOLUTE All Comers trial. The Lancet, 377(9773), 1241–1247. 
https://doi.org/10.1016/s0140-6736(11)60395-4. 
Singh, J. A., Houston, T. K., Ponce, B. A., Maddox, G., Bishop, M. J., Richman, J., ... Hawn, 
M. T. (2011). Smoking as a risk factor for short-term outcomes following primary total 
hip and total knee replacement in veterans. Arthritis Care & Research, 63(10), 1365–
1374. https://doi. org/10.1002/acr.20555. 
Singh, J. A., Jensen, M. R., Harmsen, W. S., Gabriel, S. E., & Lewallen, D. G. (2011). Cardiac 
and thromboembolic complications and mortality in patients undergoing total hip 
and total knee arthroplasty. Annals of the Rheumatic Diseases, 70(12), 2082–2088. 
https://doi.org/10.1136/ard.2010.148726. 
Singh, J. A., & Lewallen, D. G. (2011). Association of peptic ulcer disease and pulmonary 
disease with risk of periprosthetic fracture after primary total knee arthroplasty. 
Arthritis Care & Research, 63(10), 1471–1476. https://doi. org/10.1002/acr.20548. 
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., ... Breast 
Cancer International Research Group. (2011). Adjuvant trastuzumab in HER2-positive 
breast cancer. New England Journal of Medicine, 365(14), 1273–1283. 
https://doi.org/10.1056/NEJMoa0910383. 
 
 
Smith, C. R., Leon, M. B., Mack, M. J., Miller, D. C., Moses, J. W., Svensson, L. G., & 
PARTNER Trial Investigators. (2011). Transcatheter versus surgical aortic-valve 
replacement in high-risk patients. New England Journal of Medicine, 364 (23), 2187–
2198. https://doi.org/10.1056/NEJMoa1103510. 
Stefanini, G. G., Kalesan, B., Serruys, P. W., Heg, D., Buszman, P., Linke, A., ... Juni, P. 
(2011). Long-term clinical outcomes of biodegradable polymer biolimus-eluting 
stents versus durable polymer sirolimus-eluting stents in patients with coronary 
artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. The 
Lancet, 378(9807), 1940–1948. https://doi.org/10.1016/s0140-6736 (11)61672-3. 
Stiell, I. G., Nichol, G., Leroux, B. G., Rea, T. D., Ornato, J. P., Powell, J., ... ROC 
Investigators. (2011). Early versus later rhythm analysis in patients with out-of-
hospital cardiac arrest. New England Journal of Medicine, 365(9), 787–797. 
https://doi.org/10.1056/NEJMoa1010076. 
Strand, V., Smolen, J. S., van Vollenhoven, R. F., Mease, P., Burmester, G. R., Hiepe, F., ... 
Schiff, M. (2011). Certolizumab pegol plus methotrexate provides broad relief from 
the burden of rheumatoid arthritis: Analysis of patientreported outcomes from the 
RAPID 2 trial. Annals of the Rheumatic Diseases, 70(6), 996–1002. https://doi.org/10. 
1136/ard.2010.143586. 
Strangfeld, A., Eveslage, M., Schneider, M., Bergerhausen, H. J., Klopsch, T., Zink, A., & 
Listing, J. (2011). Treatment benefit or survival of the fittest: what drives the time 
dependent decrease in serious infection rates under TNF inhibition and what does this 
imply for the individual patient? Annals of the Rheumatic Diseases, 70(11), 1914– 1920. 
https://doi.org/10.1136/ard.2011.151043. 
Sundar, S., Sinha, P. K., Rai, M., Verma, D. K., Nawin, K., Alam, S., ... Modabber, F. (2011). 
Comparison of short course multidrug treatment with standard therapy for visceral 
leishmaniasis in India: An open-label, non-inferiority, randomised controlled trial. The 
Lancet, 377(9764), 477–486. https://doi.org/10.1016/s0140-6736(10)62050-8. 
Tak, P. P., Rigby, W. F., Rubbert-Roth, A., Peterfy, C. G., van Vollenhoven, R. F., Stohl, W., 
... IMAGE Investigators. (2011). Inhibition of joint damage and improved clinical 
 
 
outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: The 
IMAGE trial. Annals of the Rheumatic Diseases, 70(1), 39–46. https://doi.org/10.1136/ 
ard.2010.137703. 
Tantisira, K. G., Lasky-Su, J., Harada, M., Murphy, A., Litonjua, A. A., Himes, B. E., ... Weiss, 
S. T. (2011). Genome wide association between GLCCI1 and response to 
glucocorticoid therapy in asthma. New England Journal of Medicine, 365(13), 1173–
1183. https://doi.org/10.1056/ NEJMoa0911353. 
Taylor, P. C., Quattrocchi, E., Mallett, S., Kurrasch, R., Petersen, J., & Chang, D. J. (2011). 
Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, 
rheumatoid arthritis patients with an inadequate response to methotrexate: A 
randomised, double-blind, placebo-controlled clinical trial. Annals of the Rheumatic 
Diseases, 70(12), 2119–2125. https://doi.org/10.1136/ard.2011.151522. 
The PROTECT Investigators for the Canadian Critical Care Trials Group and the 
Australian and New Zealand Intensive Care Society Clinical Trials Group, Cook, D., 
Meade, M., Guyatt, G., Walter, S., Heels-Ansdell, D., ... Vlahakis, N. E. (2011). Dalteparin 
versus unfractionated heparin in critically ill patients. New England Journal of 
Medicine, 364(14), 1305–1314. https://doi.org/10.1056/nejmoa1014475 
Underwood, M., Mistry, D., Lall, R., & Lamb, S. (2011). Predicting response to a cognitive-
behavioral approach to treating low back pain: Secondary analysis of the BeST data 
set. Arthritis Care & Research, 63(9), 1271–1279. https://doi. org/10.1002/acr.20518. 
van de Velde, C. J., Rea, D., Seynaeve, C., Putter, H., Hasenburg, A., Vannetzel, J. M., ... 
Jones, S. E. (2011). Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): 
A randomised phase 3 trial. The Lancet, 377(9762), 321–331. 
https://doi.org/10.1016/s0140-6736(10)62312-4. 
van den Broek, M., Klarenbeek, N. B., Dirven, L., van Schaardenburg, D., Hulsmans, H. M., 
Kerstens, P. J., ... Allaart, C. F. (2011). Discontinuation of infliximab and potential 
predictors of persistent low disease activity in patients with early rheumatoid 
arthritis and disease activity score-steered therapy: Subanalysis of the BeSt study. 
 
 
Annals of the Rheumatic Diseases, 70(8), 1389–1394. 
https://doi.org/10.1136/ard.2010.147751. 
Vastesaeger, N., van der Heijde, D., Inman, R. D., Wang, Y., Deodhar, A., Hsu, B., ... Braun, 
J. (2011). Predicting the outcome of ankylosing spondylitis therapy. Annals of the 
Rheumatic Diseases, 70(6), 973–981. https://doi.org/10.1136/ ard.2010.147744. 
Velazquez, E. J., Lee, K. L., Deja, M. A., Jain, A., Sopko, G., Marchenko, A., ... STICH 
Investigators. (2011). Coronary artery bypass surgery in patients with left ventricular 
dysfunction. New England Journal of Medicine, 364(17), 1607–1616. 
https://doi.org/10.1056/NEJMoa1100356. 
Verstappen, S. M., Lunt, M., Bunn, D. K., Scott, D. G., & Symmons, D. P. (2011). In patients 
with early inflammatory polyarthritis, ACPA positivity, younger age and inefficacy of 
the first non-biological DMARD are predictors for receiving biological therapy: 
Results from the Norfolk Arthritis Register. Annals of the Rheumatic Diseases, 70(8), 
1428– 1432. https://doi.org/10.1136/ard.2010.148106. 
Vogelmeier, C., Hederer, B., Glaab, T., Schmidt, H., Ruttenvan Molken, M. P., Beeh, K. M., 
... POET-COPD Investigators. (2011). Tiotropium versus salmeterol for the prevention 
of exacerbations of COPD. New England Journal of Medicine, 364(12), 1093–1103. 
https://doi.org/10.1056/ NEJMoa1008378. 
Vons, C., Barry, C., Maitre, S., Pautrat, K., Leconte, M., Costaglioli, B., ... Franco, D. (2011). 
Amoxicillin plus clavulanic acid versus appendicectomy for treatment of acute 
uncomplicated appendicitis: An open-label, non-inferiority, randomised controlled 
trial. The Lancet, 377(9777), 1573– 1579. https://doi.org/10.1016/s0140-6736(11)60410-
8. 
Vosslamber, S., Raterman, H. G., van der Pouw Kraan, T. C., Schreurs, M. W., von 
Blomberg, B. M., Nurmohamed, M. T., ... Verweij, C. L. (2011). Pharmacological 
induction of interferon type I activity following treatment with rituximab determines 
clinical response in rheumatoid arthritis. Annals of the Rheumatic Diseases, 70(6), 
1153–1159. https://doi.org/ 10.1136/ard.2010.147199. 
 
 
Weaver, D. L., Ashikaga, T., Krag, D. N., Skelly, J. M., Anderson, S. J., Harlow, S. P., ... 
Wolmark, N. (2011). Effect of occult metastases on survival in node-negative breast 
cancer. New England Journal of Medicine, 364(5), 412–421. 
https://doi.org/10.1056/NEJMoa1008108. 
Weinstein, R. S. (2011). Clinical practice. Glucocorticoidinduced bone disease. New 
England Journal of Medicine, 365(1), 62–70. https://doi.org/10.1056/NEJMcp1012926. 
Wherrett, D. K., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., ... Type 
1 Diabetes TrialNet GAD Study Group. (2011). Antigen-based therapy with glutamic 
acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: A 
randomised double-blind trial. The Lancet, 378(9788), 319327. 
https://doi.org/10.1016/ s0140-6736(11)60895-7. 
White, P. D., Goldsmith, K. A., Johnson, A. L., Potts, L., Walwyn, R., DeCesare, J. C., ... 
Group, P. T. M. (2011). Comparison of adaptive pacing therapy, cognitive behaviour 
therapy, graded exercise therapy, and specialist medical care for chronic fatigue 
syndrome (PACE): A randomised trial. The Lancet, 377(9768), 823–836. 
https://doi.org/10.1016/ s0140-6736(11)60096-2 
White, P. M., Lewis, S. C., Gholkar, A., Sellar, R. J., Nahser, H., Cognard, C., ... HELPS Trial 
Collaborators. (2011). Hydrogel-coated coils versus bare platinum coils for the 
endovascular treatment of intracranial aneurysms (HELPS): A randomised controlled 
trial. The Lancet, 377(9778), 1655– 1662. https://doi.org/10.1016/s0140-
6736(11)60408-x. 
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., ... RAD001 in 
Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. (2011). 
Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal 
of Medicine, 364(6), 514–523. https://doi.org/10.1056/NEJMoa1009290. 
Yukawa, N., Fujii, T., Kondo-Ishikawa, S., Yoshifuji, H., Kawabata, D., Nojima, T., ... 
Mimori, T. (2011). Correlation of antinuclear antibody and anti-double-stranded DNA 
antibody with clinical response to infliximab in patients with rheumatoid arthritis: A 
 
 
retrospective clinical study. Arthritis Research & Therapy, 13(6), R213. 
https://doi.org/10.1186/ ar3546. 
Zannad, F., McMurray, J. J., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., & 
EMPHASIS-HF Study Group. (2011). Eplerenone in patients with systolic heart failure 
and mild symptoms. New England Journal of Medicine, 364(1), 11–21. 
https://doi.org/10.1056/NEJMoa1009492. 
Zeuzem, S., Andreone, P., Pol, S., Lawitz, E., Diago, M., Roberts, S., ... REALIZE Study 
Team. (2011). Telaprevir for retreatment of HCV infection. New England Journal of 
Medicine, 364(25), 2417–2428. https://doi.org/10.1056/ NEJMoa1013086. 
Received 21 March 2017; Accepted 7 June 2018 
 
 
 
Appendix C - Predetermined search terms 
Manually excluded terms   Fixed terms 
“Autoimmune 
diseases”[mesh] two[tw] vs “Age Factors”[mesh] 
“Middle aged”[mesh] up vs[tiab] “Biological 
Markers”[mesh] 
activ* up[tiab] vs[tw] “Disease 
Progression”[mesh] 
administr* up[tw] met*[mh] “Effect Modifier, 
adult* base*  “Epidemiologi 
Methods”[mesh] 
adult*[tw] base*[tiab]  “Logistic 
Models”[mesh] 
after base*[tw]  “Predictive Value of 
after[tiab] baseline  “Prognosis”[mesh] 
after[tw] baseline[tiab]  “Risk 
Factors”[mesh] 
agent* baseline[tw]  “Treatment 
Outcome”[mesh] 
agent*[tw] care  adjust* 
anti ci  analyse* 
anti[tw] ci[tiab]  associate* 
antineoplastic ci[tw]  biomarker* 
 
 
antirheumatic confiden*  correlate* 
arthritis[majr] data  determinant* 
arthritis[mh] data[tiab]  effect* 
Background data[tw]  factor* 
background[tiab] epidemiology  identify* 
background[tw] epidemiology[sh]  improve* 
Blood includ*  interact* 
blood[tw] include*  logistic 
chemotherapy[mh] include*[tiab]  mediate* 
chemotherapy[sh] include*[tw]  model* 
depart* inhibit*  moderate* 
End inhibit*[tw]  multivariable 
end[tiab] inhibitor*  multivariate 
end[tw] inhibitor*[tw]  outcome* 
find* investigat*  predict* 
 
 
(continued) Table (continued) 
Manually excluded 
terms 
 
Fixed terms 
 
find*[tiab] mean* predictive 
 
find*[tw] mean*[tiab] predictor*  
fund* mean*[tw] prognostic  
fund*[tiab] number* regress*  
fund*[tw] number*[tiab] relate*  
Hospital number*[tw] relationship*  
Iii patient*[ti] response*  
iii[tw] plus risk*  
institute* plus[tiab] stratify*  
interpret* plus[tw] subgroup*  
Metastatic point* term  
method*[mh] point*[tiab] therapy*  
Middle point*[tw] treat*  
middle[tw] receiv* univariate  
objective* receive*   
objective*[tiab] receive*[tiab]   
objective*[tw] receive*[tw]   
 
 
Over registered   
over[tw] registered[tiab]   
peptide*[mh] registered[tw]   
Per respective*   
per[tiab] respective*[tiab]   
per[tw] respective*[tw]   
protein*[majr] total*   
rheumatism total*[tiab]   
rheumatism[majr] total*[tw]   
rheumatism[mh] versus   
two versus[tiab]   
two[tiab] versus[tw]   
 
 
Appendix D - Classification of single search terms 
 
Methods-terms 
Treatment/outcome-
terms 
rat* 
“Double-blind method”[mesh]
 placebo* 
“Outcome Assessment 
(Health care)”[mesh] 
rate* 
AGE*[mh] placebo*[tiab] “Treatment 
Outcome”[mesh] 
rate*[tiab] 
age*[tiab] placebo*[tw] adverse* rate*[tw] 
aged[mesh] random* adverse*[tiab] ratio* 
analys* random*[ti] adverse*[tw] ratio*[tiab] 
analyse* random*[tiab] day* ratio*[tw] 
analyse*[tiab] random*[tw] day*[tiab] reduc* 
analyse*[tw] randomi* day*[tw] reduce* 
assess* randomise* death* reduce*[tiab] 
assess*[tiab] randomise*[ti] death*[tiab] reduce*[tw] 
assess*[tw] randomise*[tiab] death*[tw] response* 
assign* randomise*[tw] disease*[tiab] response*[tiab] 
assign*[tiab] relat* dosage response*[tw] 
assign*[tw] trial* dosage[tw] risk* 
(continued) 
 
 
Table (continued) 
Methods-terms 
 Treatment/outcome-
terms rat* 
associ* trial*[ti] dose* risk* [tiab] 
associate* trial*[tiab] dose*[tiab] risk*[tw] 
associate*[tiab] trial*[tw] dose*[tw] score* 
associate*[tw]  effect*[tiab] score*[tiab] 
blind*  event* score*[tw] 
blind*[tw]  event*[tiab] second* 
center* both methods and 
treatment or 
outcome terms 
event*[tw] second*[tiab] 
clinic*[tiab] high* second*[tw] 
clinic*[tw] differen* high*[tiab] secondary 
clinicaltrial* “Prognosis”[mesh] high*[tw] secondary[tiab] 
clinicaltrial*[tiab]  higher secondary[tw] 
clinicaltrial*[tw]  higher[tiab] sign*[tiab] 
com*[tw]  higher[tw] sign*[tw] 
combin*  improve* significan* 
compar*  improve*[tiab] significant* 
compare*  improve*[tw] significant*[tiab] 
compare*[tiab]  incre* significant*[tw] 
compare*[tw]  incre*[tiab] similar* 
 
 
control*[tiab]  incre*[tw] similar* [tiab] 
controll*  increas* similar*[tw] 
controll*[tiab]  increase* therap* 
controll*[tw]  increase*[tiab] therapeutic[mh] 
double  increase*[tw] therapeutic[tw] 
double[tw]  interv* therapy*[tiab] 
estimat*  interv*[tiab] tim* 
factor*  interv*[tw] time* 
factor*[tiab]  lower* time*[tw] 
factor*[tw]  lower*[tiab] times 
follow*  lower*[tw] treat* 
follow*[tiab]  medic* treat* 
follow*[tw]  month* treat*[ti] 
group*  month*[tiab] treat*[tiab] 
group*[tiab]  month*[tw] treat*[tw] 
group*[tw]  more treate* 
hazard*  more[tiab] treate*[tiab] 
hazard*[tiab]  more[tw] treate*[tw] 
hazard*[tw]  mortality week* 
 
 
intent*  mortality[tw] week*[tiab] 
intent*[tiab]  outcome* week*[tw] 
intent*[tw]  outcome*[tiab] year* 
model*[tw]  outcome*[tw] year*[tiab] 
multicenter  primar* year*[tw] 
multicenter[tw]  primary*  
phase  primary*[tiab]  
phase[tw]  primary*[tw]  
 
